05 January 2021
EMA/CHMP/708314/2020
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 09-12 November 2020

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The participants had no objection to hold the meeting remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See November 2020 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 09-12 November 2020.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 16 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 09-12 November 2020

The CHMP adopted the agenda.

1.3. Adoption of the minutes

ORGAM minutes from meeting held on 3 November 2020.

The Minutes of the November 2020 CHMP ORGAM meeting held on 3 November 2020, together with all decisions taken at that meeting, were adopted.

CHMP minutes for 14-17 September 2020.

The CHMP adopted the September 2020 minutes.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. glucagon - EMEA/H/C/005391

treatment of severe hypoglycaemia in adults, adolescents and children aged 2 years and over with diabetes mellitus.

Scope: Possible oral explanation

Action: Oral explanation to be held on Wednesday, 11 November 2020 at 09:00

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 30.04.2020.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.1.2. somapacitan - Orphan - EMEA/H/C/005030

Novo Nordisk A/S; indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD).

Scope: Oral explanation,

Updated draft list of experts for the ad-hoc expert group (AHEG) meeting scheduled on 29 October 2020 adopted via written procedure on 28 October 2020,

AHEG report

Action: Oral explanation to be held on Tuesday, 10 November 2020 at 16:00

List of Outstanding Issues adopted on 17.09.2020, 25.06.2020. List of Questions adopted on 30.01.2020.

Participation of a patient representative.

The CHMP noted the ad-hoc expert group meeting report.

An oral explanation was held on Tuesday, 10 November 2020. The presentation by the applicant focused on the clinical data in support of the application.

See 3.2

2.2. Re-examination procedure oral explanations

2.2.1. Elzonris - tagraxofusp - Orphan - EMEA/H/C/005031

Stemline Therapeutics B.V.; treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Scope: Oral explanation,

Draft list of experts for the SAG Oncology meeting scheduled on 4 November 2020 adopted via written procedure on 4 November 2020,

SAG report

Action: Oral explanation to be held on Tuesday, 10 November 2020 at 14:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.07.2020. List of Outstanding Issues adopted on 26.03.2020, 25.06.2019. List of Questions adopted on 24.04.2019.

The CHMP noted the SAG report.

An oral explanation was held on Tuesday, 10 November 2020. The presentation of the applicant focused on the grounds for refusal.

See 3.5

2.2.2. Gamifant - emapalumab - Orphan - EMEA/H/C/004386

Swedish Orphan Biovitrum AB; treatment of paediatric patients with primary haemophagocytic lymphohistiocytosis (HLH).

Scope: Oral explanation,

Draft list of experts for the ad-hoc expert group (AHEG) meeting scheduled on 30 October 2020 adopted via written procedure on 28 October 2020,

AHEG report

Action: Oral explanation to be held on Tuesday, 10 November 2020 at 09:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.07.2020. List of Outstanding Issues adopted on 25.06.2020, 27.06.2019. List of Questions adopted on 13.12.2018.

Participation of a patient representative.

The CHMP noted the ad-hoc expert group meeting report.

An oral explanation was held on Tuesday, 10 November 2020. The presentation of the applicant focused on the grounds for refusal.

See 3.5

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Onbevzi - bevacizumab - EMEA/H/C/005640

Samsung Bioepis NL B.V.; the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.2. Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386

Roche Registration GmbH; treatment of early breast cancer, metastatic breast cancer.

Scope: Opinion

Action: For adoption

Fixed combination application (Article 10b of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.3. Roclanda - netarsudil / latanoprost - EMEA/H/C/005107

Aerie Pharmaceuticals Ireland Limited; reduction of elevated intraocular pressure.

Scope: Opinion

Action: For adoption

Fixed combination application (Article 10b of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 30.04.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 11.11.2020.

The summary of opinion was circulated for information.

3.1.4. Xofluza - baloxavir marboxil - EMEA/H/C/004974

Roche Registration GmbH; treatment of influenza in patients aged 12 and above, including patients at high risk of developing influenza-related complications and for post-exposure prophylaxis of influenza in individuals aged 12.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 26.03.2020.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that baloxavir marboxil is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 09.11.2020.

The summary of opinion was circulated for information.

Post meeting note: The final SmPC was adopted via written procedure on 13.11.2020.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. estetrol / drospirenone - EMEA/H/C/005336

oral contraceptive.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.06.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. trastuzumab deruxtecan - EMEA/H/C/005124

Accelerated assessment

treatment of unresectable or metastatic HER2-positive breast cancer.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. estetrol / drospirenone - EMEA/H/C/005382

oral contraception.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.06.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. glucagon - EMEA/H/C/005391

treatment of severe hypoglycaemia in adults, adolescents and children aged 2 years and over with diabetes mellitus.

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 30.04.2020.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP agreed that an oral explanation was not needed at this time.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. somapacitan - Orphan - EMEA/H/C/005030

Novo Nordisk A/S; indicated for the replacement of endogenous growth hormone (GH) in adults with growth hormone deficiency (AGHD).

Scope: Oral explanation,

Updated draft list of experts for the ad-hoc expert group meeting scheduled on 29 October 2020 adopted via written procedure on 28 October 2020,

AHEG report

Action: Oral explanation to be held on Tuesday, 10 November 2020 at 16:00

List of Outstanding Issues adopted on 17.09.2020, 25.06.2020. List of Questions adopted on 30.01.2020.

Participation of a patient representative.

The CHMP noted the ad-hoc expert group meeting report.

An oral explanation was held on Tuesday, 10 November 2020. The presentation by the applicant focused on the clinical data in support of the application.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.6. adalimumab - EMEA/H/C/005188

treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa (HS), Crohn’s disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 23.07.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. abiraterone acetate - EMEA/H/C/005649

treatment of prostate cancer in adult men.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - ATMP - EMEA/H/C/004731

Celgene Europe BV; treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

Scope: List of questions

Action: For information

The CHMP was updated on discussions at the CAT. The Committee discussed the issues identified in this application.

The Committee endorsed the list of questions as adopted by the CAT.

3.3.3. dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. risdiplam - Orphan - EMEA/H/C/005145

Accelerated assessment

Roche Registration GmbH; treatment of spinal muscular atrophy (SMA)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

3.3.5. imatinib - EMEA/H/C/005595

treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES), eosinophilic leukaemia (CEL), Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST), and unresectable dermatofibrosarcoma protuberans (DFSP)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. abiraterone acetate - EMEA/H/C/005408

treatment of metastatic prostate cancer.

Scope: Letter from the applicant dated 27 October 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in October 2020.

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 30.01.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in October 2020.

3.4.2. risperidone - EMEA/H/C/005406

treatment of schizophrenia

Scope: Request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in October 2020.

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in October 2020.

3.4.3. satralizumab - Orphan - EMEA/H/C/004788

Roche Registration GmbH; treatment of adult and adolescent patients from 12 years of age with neuromyelitis optica spectrum disorders (NMOSD).

Scope: Letter from the applicant dated 22 October 2020 requesting an extension of clock-stop to respond to the list of outstanding issues adopted in May 2020.

Action: For adoption

List of Outstanding Issues adopted on 28.05.2020. List of Questions adopted on 10.12.2019.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of outstanding issues adopted in May 2020.

3.4.4. bevacizumab - EMEA/H/C/005433

indicated in adults for the treatment of neovascular macular degeneration associated with aging and diabetes.

Scope: Letter from the applicant dated 27 October 2020 requesting an extension of clock-stop to respond to the list of questions adopted in September 2020.

Action: For adoption

List of Questions adopted on 17.09.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in September 2020.

3.4.5. tirbanibulin mesilate - EMEA/H/C/005183

topical field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis.

Scope: Letter from the applicant dated 21 October 2020 requesting an extension of clock-stop to respond to the list of questions adopted in June 2020.

Action: For adoption

List of Questions adopted on 25.06.2020.

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in June 2020.

3.4.6. tafasitamab - Orphan - EMEA/H/C/005436

Morphosys AG; is indicated in combination with lenalidomide followed by tafasimab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).

Scope: Letter from the applicant dated 09 November 2020 requesting an extension of clock-stop to respond to the list of questions adopted in September 2020.

List of Questions adopted on 17.09.2020

The CHMP agreed to the request by the applicant for an extension of clock-stop to respond to the list of questions adopted in September 2020.

3.4.7. eladocagene exuparvovec - Orphan - ATMP - EMEA/H/C/005352

PTC Therapeutics International Limited; treatment of aromatic L-amino aciddecarboxylase (AADC) deficiency

Scope: Request by the applicant for an extension to the clock stop to respond to the list of questions adopted in May 2020.

Action: For information

List of Questions adopted on 20.05.2020.

The CHMP noted the extension of clock stop as adopted by CAT.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Aplidin - plitidepsin - Orphan - EMEA/H/C/004354

Pharma Mar, S.A.; treatment of multiple myeloma.

Scope: Implementation of Judgement of the General Court in Case-T-594/18, confirmation of rapporteurs, draft timetable

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion re-examination adopted on 22.03.2018. Opinion adopted on 14.12.2017

The timetable will be adopted via written procedure.

3.5.2. Elzonris - tagraxofusp - Orphan - EMEA/H/C/005031

Stemline Therapeutics B.V.; treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Scope: Oral explanation,

Draft list of experts for the SAG Oncology meeting scheduled on 4 November 2020 adopted via written procedure on 4 November 2020,

SAG report

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.07.2020. List of Outstanding Issues adopted on 26.03.2020, 25.06.2019. List of Questions adopted on 24.04.2019.

See 2.2

An oral explanation was held on Tuesday, 10 November 2020. The presentation of the

applicant focused on the grounds for refusal.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation under exceptional circumstances by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 12.11.2020.

The summary of opinion was circulated for information.

3.5.3. Gamifant - emapalumab - Orphan - EMEA/H/C/004386

Swedish Orphan Biovitrum AB; treatment of paediatric patients with primary Haemophagocytic Lymphohistiocytosis (HLH).

Scope: Oral explanation,

Report from the ad-hoc expert group meeting scheduled on 30 October 2020

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 23.07.2020. List of Outstanding Issues adopted on 25.06.2020, 27.06.2019. List of Questions adopted on 13.12.2018.

See 2.2

The CHMP noted the ad-hoc expert group meeting report.

An oral explanation was held on Tuesday, 10 November 2020. The presentation of the applicant focused on the grounds for refusal.

The CHMP adopted a negative opinion by majority (27 negative votes out of 29 votes), recommending the refusal of the marketing authorisation.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The divergent position (Sinan B. Sarac, John Joseph Borg) was appended to the opinion.

The CHMP noted the EMA question and answer document.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Puldysa - idebenone - Orphan - EMEA/H/C/005123

Santhera Pharmaceuticals (Deutschland) GmbH; treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) not using glucocorticoids.

Scope: Withdrawal of initial marketing authorisation application

Action: For information

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 30.04.2020. List of Questions adopted on 17.10.2019.

The CHMP noted the withdrawal of initial marketing authorisation application.

3.7.2. Roctavian - valoctocogene roxaparvovec - Orphan - ATMP - EMEA/H/C/004749

Accelerated assessment

BioMarin International Limited; treatment of haemophilia A.

Scope: Withdrawal of initial marketing authorisation application

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 24.04.2020.

The CHMP noted the withdrawal of initial marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Nuceiva - botulinum toxin type A - EMEA/H/C/004587/X/0005

Evolus Pharma Limited

Rapporteur: Peter Kiely, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension application to add a new strength of 50 U for botulinum toxin type A for powder for solution for injection in vial (glass), for intramuscular administration."

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP noted the letter of recommendation dated 09.11.2020.

4.1.2. Pradaxa - dabigatran etexilate - EMEA/H/C/000829/X/0122/G

Boehringer Ingelheim International GmbH

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension application to add two new pharmaceutical forms for Pradaxa (coated granules (20 mg, 30 mg, 40 mg, 50 mg, 110 mg, 150 mg) and powder and solvent for oral solution (6.25 mg/ml)), grouped with:
- A type II variation (C.I.6.a) - Extension of indication to include new indication for Pradaxa 75 mg, 110 mg, 150 mg capsules based on the paediatric trials 1160.106 and 1160.108. As a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.7, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet and labelling are updated in accordance. In addition, the marketing authorisation holder took the opportunity to update the list of local representatives in the package leaflet. The RMP version 37.0 has also been submitted.
- Type IB (B.I.b.1.c)
- Type IA (B.I.b.1.b)
- Type IB (B.I.b.1.d)
- Type IA (B.I.b.2.a)
- Type IA (B.I.b.1.d)
- Type IA (B.I.d.1.a.1)
- Type IA (B.II.d.1.a)
- Type IB (B.II.d.1.d)
- Type IA (B.II.d.2.a)
- Type IA (B.II.c.1.c)"

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020, 23.07.2020. List of Questions adopted on 27.02.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.3. Tivicay - dolutegravir - EMEA/H/C/002753/X/0058/G

ViiV Healthcare B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber

Scope: "- Extension application to add a new pharmaceutical form associated with new strength (5 mg dispersible tablet). The new presentation is indicated for the treatment of HIV infected children from 4 weeks of life and weighing at least 3 kilograms.

- Type II variation (C.I.4) to update the currently approved Product Information, Labelling and Package Leaflet for the existing film-coated tablets (10 mg, 25 mg and 50 mg) for children 6 years and older and weighing at least 15 kg.

In addition, the applicant took the opportunity to amend section 4.1 of SmPC the indication for the approved Tivicay film-coated tablets to clarify that children should be "aged at least 6 years" as the current approved indication is inclusive of those aged 6 years.

The RMP (version 16) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 15.10.2020. List of Questions adopted on 28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.4. Trimbow - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004257/X/0008/G

Chiesi Farmaceutici S.p.A.

Rapporteur: Janet Koenig, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension of indication to add 'Maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year' for Trimbow 87 µg/5 µg/9 µg. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and labelling are updated in accordance. In addition, the MAH took the opportunity to revise the product information in line with the EC guideline on excipients. Furthermore, the PI is brought in line with the latest QRD template version 10.1. The risk management plan version 6.5 is acceptable."

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 26.03.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP

recommendations.

4.1.5. Xarelto - rivaroxaban - EMEA/H/C/000944/X/0074/G

Bayer AG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form, granules for oral suspension, 1 mg/ml.

Extension of indication to include treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in term neonates, infants and toddlers, children and adolescents aged less than 18 years following initiation of standard anticoagulation treatment for Xarelto 15 and 20 mg tablets.

As a consequence, sections 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly.

In addition, sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC is updated for all other dose strengths (2.5/10 and 15/20 mg initiation packs) of Xarelto and corresponding sections of the Package Leaflet. Section 4.4 has been updated with regards to sodium content according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668).

The RMP version 12.1 has also been submitted."

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020, 23.07.2020. List of Questions adopted on 30.04.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Diacomit - stiripentol - EMEA/H/C/000664/X/0032

BIOCODEX

Rapporteur: Alar Irs, PRAC Rapporteur: Maia Uusküla

Scope: "Extension application to add a new strength of 100 mg capsules. The RMP (version 2.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 25.06.2020.

The Committee discussed the issues identified in this application, mainly concerning quality aspects and the environmental risk assessment.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.2. Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781/X/0014/G

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Annika Folin

Scope: "Extension application to introduce a new strength (184 mcg/55 mcg/22 mcg) grouped with a type II variation (C.I.6.a) to add a new indication (asthma). Whilst the new indication is applicable also to the existing presentations (EU/1/17/1237/001-3), the new strength is indicated only for the treatment of asthma. The RMP (version 2.2) is updated in accordance."

Action: For adoption

List of Questions adopted on 25.06.2020.

The Committee discussed the issues identified in this application, mainly concerning clinical efficacy and safety aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.3. Lacosamide Accord - lacosamide - EMEA/H/C/004443/X/0007

Accord Healthcare S.L.U.

Rapporteur: John Joseph Borg, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form (solution for infusion), a new strength (10 mg/ml) and a new route of administration (intravenous use)."

Action: For adoption

List of Questions adopted on 26.03.2020.

The Committee discussed the issues identified in this application, mainly concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.4. Sirturo - bedaquiline - Orphan - EMEA/H/C/002614/X/0036/G

Janssen-Cilag International NV

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to add a new strength (20 mg tablets) grouped with a type II variation (C.I.6) to extend the existing Sirturo indication to include paediatric patients aged from 5 years to less than 18 years of age and weighing more than 15 kg, based on the

results of the week 24 analysis of Cohort 2 (paediatric subjects aged ≥5 to <12 years) of study TMC207-C211. Sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 and the product leaflet are updated to support the extended indication. The RMP (version 4.4) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 30.04.2020.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.5. Temybric Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/005254/X/0004/G

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Annika Folin

Scope: "Extension application to introduce a new strength (184 mcg/55 mcg/22 mcg) grouped with a type II variation (C.I.6.a) to add a new indication (asthma). Whilst the new indication is applicable also to the existing presentations (EU/1/19/13781237/001-3), the new strength is indicated only for the treatment of asthma. The RMP (version 2.2) is updated in accordance."

Action: For adoption

List of Questions adopted on 25.06.2020.

The Committee discussed the issues identified in this application, mainly concerning clinical efficacy and safety aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.6. Tepadina - thiotepa - EMEA/H/C/001046/X/0036

ADIENNE S.r.l.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (400 mg powder and solvent for solution for infusion)."

Action: For adoption

List of Outstanding Issues adopted on 17.09.2020. List of Questions adopted on 26.03.2020.

The Committee discussed the issues identified in this application, concerning a clinical safety aspect and the similarity assessment.

The Committee adopted the CHMP recommendation and scientific discussion together with the 2nd list of outstanding issues and a specific timetable.

4.2.7. Trelegy Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363/X/0012/G

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Annika Folin

Scope: "Extension application to introduce a new strength (184 mcg/55 mcg/22 mcg) grouped with a type II variation (C.I.6.a) to add a new indication (asthma). Whilst the new indication is applicable also to the existing presentations (EU/1/17/1236/001-3), the new strength is indicated only for the treatment of asthma. The RMP (version 2.2) is updated in accordance."

Action: For adoption

List of Questions adopted on 25.06.2020.

The Committee discussed the issues identified in this application, mainly concerning clinical efficacy and safety aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.8. Tysabri - natalizumab - EMEA/H/C/000603/X/0116

Biogen Netherlands B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection), associated with a new strength (150 mg) and a new route of administration (subcutaneous use). The RMP (version 26.1) is updated accordingly."

Action: For adoption

List of Questions adopted on 23.07.2020.

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/X/0026

Eurocept International B.V.

Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (350 mg/ml oral solution). The RMP (version 0.1) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning bioequivalence

aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Pheburane - sodium phenylbutyrate - EMEA/H/C/002500/X/0028

Eurocept International B.V.

Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (500 mg film-coated tablets). The RMP (version 0.1) is updated in accordance."

Action: For adoption

The Committee discussed the issues identified in this application, concerning bioequivalence aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Brilique - ticagrelor - EMEA/H/C/001241/II/0047/G

AstraZeneca AB

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include, in co-administration with acetylsalicylic acid (ASA), the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) without a history of myocardial

infarction who have undergone percutaneous coronary intervention (PCI) based on the final results of study D513BC00001 (THEMIS), a phase III multinational, randomised, double-blind, placebo controlled study to evaluate the effect of ticagrelor twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with T2DM. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. Update of section 4.8 of the SmPC regarding with new safety information on traumatic haemorrhages based on the final results from study D513BC00001 (THEMIS) and data from the ticagrelor clinical development programme and post-marketing data. The package leaflet is updated in accordance. The RMP version 12 has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.05.2020, 14.11.2019.

The Committee discussed the issues identified in this application, mainly concerning clinical efficacy and safety aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.2. Doptelet - avatrombopag - EMEA/H/C/004722/II/0004/G

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. Consequently, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. Additionally, the SmPC section 5.3 is updated with data from juvenile toxicity studies. Furthermore, an additional pack size has been introduced with subsequent updates of sections 6.5 and 8.0 of the SmPC. The package leaflet and labelling are updated in accordance. Version 2.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020, 28.05.2020.

The Committee discussed the issues identified in this application, mainly concerning pharmacokinetics, SmPC changes and the RMP.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.3. Kyprolis - carfilzomib - Orphan - EMEA/H/C/003790/II/0045

Amgen Europe B.V.

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Alexandre Moreau

Scope: "Extension of existing indication to include combination of Kyprolis with daratumumab and dexamethasone. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance."

Action: For adoption

Request for Supplementary Information adopted on 28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.4. Lonquex - lipegfilgrastim - EMEA/H/C/002556/II/0058/G

Teva B.V.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of the paediatric population for Lonquex and introduction of an age appropriate presentation in vials. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The package leaflet is updated in accordance. Version 12.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the package leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.1."

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning non-clinical and clinical aspects.

The Committee adopted a request for supplementary information.

The CHMP agreed to the request by the company for an extension to the clock stop with a specific timetable.

5.1.5. Nulojix - belatacept - EMEA/H/C/002098/II/0070

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Filip Josephson, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include the use of belatacept in conversion from a calcinerin inhibitor-based regimen to a belatacept-based regimen post transplantation. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 18.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.1 and requirement on sodium excipients is added."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. Xyrem - sodium oxybate - EMEA/H/C/000593/II/0076

UCB Pharma S.A.

Rapporteur: Bruno Sepodes, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include adolescents and children older than 7 years for Xyrem. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The package leaflet is updated in accordance. The updated version (9.0) of the RMP was submitted."

Action: For adoption

Request for Supplementary Information adopted on 17.09.2020, 28.05.2020, 12.12.2019, 29.05.2019, 15.11.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.7. Zinforo - ceftaroline fosamil - EMEA/H/C/002252/II/0048

Pfizer Ireland Pharmaceuticals

Rapporteur: Alar Irs

Scope: "Extension of indication for the treatment of community acquired pneumonia (CAP) to include concurrent bacteraemia due to Streptococcus pneumoniae (SP) for all age groups, based on the results of previously submitted studies: FOCUS 1 (study P903-08) and FOCUS 2 (study P903-09), paediatric CAP study (study P903-31) and relevant post-marketing safety experience with ceftaroline for bacteraemic Streptococcus pneumoniae CAP. As a consequence, sections 4.1 and 5.1 of the SmPC are updated accordingly. No RMP has been provided within this application."

Action: For adoption

Request for Supplementary Information adopted on 23.07.2020, 12.12.2019.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.8. WS1840
OPDIVO - nivolumab - EMEA/H/C/003985/WS1840/0089
Yervoy - ipilimumab - EMEA/H/C/002213/WS1840/0084

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of adult patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) for combination treatment with Opdivo and Yervoy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet is updated in accordance. Version 18.0 for Opdivo and version 29.0 for Yervoy of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1. Kaftrio - elexacaftor / tezacaftor / ivacaftor - Orphan - EMEA/H/C/005269/II/0001

Vertex Pharmaceuticals (Ireland) Limited; treatment of cystic fibrosis.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Martin Huber

Scope: "Extension of indication of Kaftrio to patients with CF aged 12 years and older who have at least one F508del mutation in the CFTR gene, regardless of the second allele (F/any). Efficacy data are summarised from study 104, which was conducted in subjects heterozygous for F508del and a gating (G) or residual function (RF) mutation (F/G and F/RF genotypes). As a consequence, update of SmPC sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 are requested. Package insert is updated accordingly. The RMP is updated version 1.1",

Letter from third party,

Response letter

Action: For adoption

The CHMP noted the letter from a third party and adopted the response letter.

5.2.2. Xtandi - enzalutamide - EMEA/H/C/002639/II/0047/G

Astellas Pharma Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "C.1.6: Extension of indication to include the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) for Xtandi in combination with androgen deprivation therapy; As a consequence, sections 4.1, 4.7, 4.8, 5.1, 5.3 and 6.6 of the SmPC

are updated. Furthermore, the MAH took the opportunity to make corrections to section 4.7. The Package Leaflet is updated in accordance. The RMP version 13.0 has also been submitted.
C.1.4: Update of section 5.1 of the SmPC based the 5-year Overall Survival (OS) results obtained from the PREVAIL study (MDV310003), a phase 3 study of enzalutamide in chemotherapy naïve patients with metastatic prostate cancer that progressed on ADT."

Letter by the applicant dated 09 November 2020 requesting an extension to the clock stop to respond to the Request for Supplementary Information adopted on 28.05.2020

Action: For adoption

Request for Supplementary Information adopted on 28.05.2020, 17.10.2019.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the Request for Supplementary Information adopted on 28.05.2020

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. odevixibat - H0004691

progressive familial intrahepatic cholestasis (PFIC).

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.2. capecitabine - H0005683

indicated as an adjuvant treatment after surgery of colon cancer:

- for the treatment of metastatic colorectal cancer;

- for first-line treatment of advanced gastric cancer;

- metastatic breast cancer.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.3. pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - H0005451

active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in adults aged 18 years and older.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.1.4. temozolomide - H0005684

indicated for newly diagnosed malignant glioma such as glioblastoma multiforme and anaplastic astrocytoma.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the information.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 6 recommendations for eligibility to PRIME: 3 were accepted and 3 were denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Alpivab - peramivir - EMEA/H/C/004299

Biocryst UK Limited

Rapporteur: Ingrid Wang, Co-Rapporteur: Janet Koenig

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of marketing authorisation.

9.1.2. Dukoral - cholera vaccine (inactivated, oral) - EMEA/H/C/00476/II/0062/G

Valneva Sweden AB

Rapporteur: Kristina Dunder

Scope: Adoption of revised opinion documents

Action: For adoption

The CHMP adopted the revised opinion documents by consensus.

9.1.3. Ervebo - recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0008/G

Merck Sharp & Dohme B.V.

Rapporteur: Christophe Focke

Scope: "(Type IB) B.II.b.3.z -
(Type II) C.I.11.b - Update to Annex II to delete specific obligations 2 and 4 and conversion to marketing authorisation not subject to specific obligations. In addition, the MAH is updating section 5.1 of the SmPC and section 6 of the package leaflet to delete the conditional marketing authorisation details.
The MAH has taken the opportunity to propose a progress report to be provided following a post-authorisation measure"

Action: For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.4. Isturisa – osilodrostat - EMEA/H/C/004821

Recordati Rare Diseases; indicated for the treatment of endogenous Cushing's syndrome in adults.

Rapporteur: Kristina Dunder, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Eva A. Segovia

Scope: Adoption of revised opinion documents

Action: For adoption

The CHMP adopted the revised opinion documents by consensus.

9.1.5. Mysimba – naltrexone hydrochloride/ bupropion hydrochoride - EMEA/H/C/003687/ANX/001.5

Orexigen Therapeutics Ireland Limited

Rapporteur: Kirstine Moll Harboe, Co-Rapporteur: Andrea Laslop

Scope: MAH Response to ANX-001.4 [PASS, Study no. NB-CVOT Study 2] as adopted in June 2020: A multicentre, randomised, double-blind, placebo-controlled, phase 4 study to assess the effect of naltrexone extended release (ER) /bupropion ER on the occurrence of major adverse cardiovascular events (MACE) in overweight and obese subjects.

Action: For adoption

The Committee discussed the issues identified, concerning the PASS protocol.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.6. Nulojix - belatacept - EMEA/H/C/002098/II/0065/G

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Filip Josephson

Scope: "B.I.a.2.c
B.I.b.1.c
B.I.b.2.b"

Action: For adoption

Request for Supplementary Information adopted on 12.03.2020.

The Committee discussed the issues identified in this application, mainly relating to quality and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.7. Ocaliva - obeticholic acid - EMEA/H/C/004093/R/0023, Orphan

Intercept Pharma International Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: Renewal of conditional marketing authorisation

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

9.1.8. Udenyca - pegfilgrastim - EMEA/H/C/004413

ERA Consulting GmbH; treatment of neutropenia.

Rapporteur: Martina Weise, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst

Scope: Withdrawal of marketing authorisation

Action: For information

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

The CHMP noted the withdrawal of marketing authorisation.

9.1.9. Veklury - remdesivir - EMEA/H/C/005622/II/0012

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig

Scope: "Submission of the final D28 mortality data by ordinal scale categories of study COUS-540-5776 (NIAID-ACTT1), listed as a specific obligation in the Annex II of the product information, in order to confirm the efficacy and safety of remdesivir in patients on invasive mechanical ventilation and extracorporeal membrane oxygenation (IMV/ECMO). In addition, the marketing authorisation holder discuss the potential imbalance in the use of corticosteroids and effect modification in study CO-US-540-5776. As a consequence, Annex II is updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - EMEA/H/A-31/1471

MAHs: various

Overall Rapporteur: Martina Weise, Co-Rapporteurs:
Candesartan: Kristina Dunder, Irbesartan: Concepcion Prieto Yerro, Losartan: Johann Lodewijk Hillege, Olmesartan: Milena Stain, Valsartan: Armando Genazzani

Scope: Impact of the Article 5(3) referral on nitrosamines in human medicinal products on the referral under article 31 of Directive 2001/83/EC for sartans medicinal products containing a tetrazole ring.

Action: For adoption

The CHMP adopted an opinion by consensus recommending to align the recommendations for limiting nitrosamine impurities in sartan medicines with recent recommendations it issued for other classes of medicines. In line with previous recommendations, companies should have appropriate control strategies to prevent or limit the presence of nitrosamine impurities as much as possible and, where necessary, improve their manufacturing processes. Companies should also evaluate the risk of nitrosamines being present in their medicines and carry out appropriate tests.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The CHMP adopted the EMA public health communication.

10.6.2. Esmya (CAP); NAP - ulipristal acetate - EMEA/H/A-31/1496

MAH(s): Gedeon Richter Plc.; various

Referral PRAC Rapporteur: Annika Folin, Referral PRAC Co-Rapporteur: Menno van der Elst, CHMP Rapporteurs (Esmya): Kristina Dunder, CHMP Co-Rapporteur (Esmya): Paula Boudewina van Hennik

Scope: CHMP Opinion

Action: For adoption

Review of the benefit-risk balance following notification by the European Commission of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data; PRAC recommendation.

Having considered the PRAC recommendation, the CHMP adopted an opinion by majority (19 votes out of 31 votes), recommending to restrict the use of medicines containing ulipristal acetate 5 mg (Esmya and generic medicines) as a result of cases of serious liver injury. The medicines can now only be used to treat uterine fibroids in premenopausal women for whom surgical procedures (including uterine fibroid embolisation) are not appropriate or have not worked. The medicines must not be used for controlling symptoms of uterine fibroids while awaiting surgical treatment.

The member from Iceland agreed with the CHMP recommendation, the member from Norway did not agree.

The divergent position (Sinan B. Sarac, Christophe Focke, Ewa Balkowiec Iskra, Kristina Dunder, Bruno Sepodes, Ilko Getov, Jan Mueller-Berghaus, Alexandre Moreau, Armando Genazzani, Martina Weise, Jayne Crowe, Konstantinos Markopoulos, Bjorg Bolstad) was appended to the opinion.

The CHMP adopted the EMA public health communication.

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

November 2020 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Election of CHMP Co-opted Members

Election of CHMP co-opted member in light of the expiry of the mandate of co-opted member Jan Mueller-Berghaus on 13 November 2020.

Agreed areas of expertise: Quality, safety and efficacy of biological medicinal products, including advanced therapies and with specific emphasis on vaccines.

Action: For adoption

The CHMP re-elected Jan Mueller-Berghaus as CHMP co-opted member for another 3 year term.

14.1.2. Update on CHMP Co-opted Members

Call for nomination of CHMP co-opted member in light of Koenraad Norga's resignation as CHMP co-opted member as of 30 September 2020.

Adoption of the area of expertise following discussions at ORGAM.

Action: For adoption

The CHMP agreed on the area of expertise:

Pharmaco-Epidemiology; especially for methodology (bias, effect modifications etc.) and interpretation of data, in particular study designs (observational studies, RWD etc.), strengths and weaknesses.

Please send nominations. The election is planned at the January 2021 Plenary.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 26-29 October 2020

Action: For information

The CHMP noted the summary of recommendations and advice.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for November 2020

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at November 2020 PDCO

Action: For information

The CHMP noted the information.

Report from the PDCO meeting held on 10-13 November 2020

Action: For information

The CHMP noted the report.

14.2.3. Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human (CMDh)

Chair: Kora Doorduyn-van der Stoep

CMDh questions to CHMP on NDMA detected in metformin containing medicinal products

Action: For adoption

The CHMP noted the question from the CMDh and provided a response.

Proposal for Multidisciplinary Expert Group on Interim limits

Action: For discussion

The CHMP noted the update to support setting interim limits for critical products with nitrosamines.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP November 2020 meeting to CHMP for adoption:

- 8 reports on products in scientific advice and protocol assistance
- 5 reports on products in pre-authorisation procedures
- 3 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 26-29 October 2020. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the update.

15.1.2. Reflection paper – EMA considerations on Covid-19 vaccines approval

Action: For discussion

The CHMP discussed the reflection paper and agreed to the presented principles.

15.1.3. COVID-19 Vaccine (ChAdOx1-S [recombinant]) - H0005675

intramuscular (IM) injection of vaccine for coronavirus disease 2019 (COVID-19).

Scope: Updated non-clinical rolling review timetable adopted via written procedure on 6 November 2020

Action: For information

The CHMP noted the updated timetable.

15.1.4. COVID-19 mRNA vaccine (nucleoside-modified) - H0005735

is indicated for prophylactic vaccination against Severe Acute Respiratory Syndrome (SARS)-CoV-2.

Scope: Updated non-clinical timetable adopted via written procedure on 6 November 2020

Action: For information

The CHMP noted the updated timetable.

Scope: 2nd Rolling Review timetable adopted via written procedure on 30. October 2020

Action: For information

The CHMP noted the timetable for the Rolling Review adopted via written procedure.

Post meeting note: Following the November Plenary the 2nd Rolling Review timetable was shortened and adopted via written procedure on 17.11 2020

15.1.5. COVID-19 vaccine - EMEA/H/C/005791

Active immunization against coronavirus disease 2019 (COVID-19) caused by the SARSCoV-2 virus in persons 18 years of age and older.

Scope: 1st Rolling Review timetable adopted via written procedure on 17.11.2020

Action: For information

The CHMP noted the updated timetable.

15.1.6. CoreRMP19 requirements and guidance for COVID-19 vaccines

Scope: Consideration on core requirements for RMPs of COVID-19 vaccines and CoreRMP19 guidance for adoption via written procedure on 5 November 2020

Action: For information

The CHMP noted the document which was adopted via written procedure on 5 November 2020.

15.1.7. Invitation to participate in a MCDA (Multi Criteria Decision Analysis) exercise for benefit risk

Action: For information

The CHMP noted the update.

16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 09-12 November 2020 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Milena Stain	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Emilia Mavrokordatou	Alternate	Cyprus	No restrictions applicable to this meeting	
Ondřej Slanař	Member	Czech Republic	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czech Republic	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No restrictions applicable to this meeting	
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No participation in discussions, final deliberations and voting on	Tysabri - natalizumab - EMEA/H/C/000603/X/0116 Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - EMEA/H/A-31/1471

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No restrictions applicable to this meeting	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czech Republic	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Christina Hojelse	Expert - via telephone*	Denmark	No interests declared	
Helle Mulvad	Expert - via telephone*	Denmark	No interests declared	
Steen Werner Hansen	Expert - via telephone*	Denmark	No restrictions applicable to this meeting	
Tina Visholm Jensen	Expert - via telephone*	Denmark	No interests declared	
Gritta Janka	Expert - via telephone*	Germany	No interests declared	
Susan Webb	Expert - via telephone*	Spain	No restrictions applicable to this meeting	
Filip van Nuffel	Expert - via Adobe*	Belgium	No interests declared	
Olga Kholmaskikh	Expert - via Adobe*	Belgium	No interests declared	
Aaron Sosa	Expert - via Adobe*	Denmark	No restrictions applicable to this meeting	
Mette Linnert Jensen	Expert - via Adobe*	Denmark	No interests declared	
Mogens Westergaard	Expert - via Adobe*	Denmark	No interests declared	
Daniel Morales	Expert - via Adobe*	Independent scientific expert	No interests declared	
Brigitta Grundmark	Expert - via Adobe*	Independent scientific expert	No interests declared	
Muriel Uzzan	Expert - via Adobe*	France	No interests declared	
Philippe Zamia	Expert - via Adobe*	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Tiphaine Vaillant	Expert - via Adobe*	France	No interests declared	
Andreas Brandt	Expert - via Adobe*	Germany	No interests declared	
Christoph Unkrig	Expert - via Adobe*	Germany	No interests declared	
Elena Wolff-Holz	Expert - via Adobe*	Germany	No interests declared	
Katrin Buss	Expert - via Adobe*	Germany	No interests declared	
Martin Huber	Expert - via Adobe*	Germany	No interests declared	
Martina Schussler-Lenz	Expert - via Adobe*	Germany	No interests declared	
Maxim Frizler	Expert - via Adobe*	Germany	No interests declared	
Regine Lehnert	Expert - via Adobe*	Germany	No interests declared	
Stephanie Buchholz	Expert - via Adobe*	Germany	No interests declared	
Uta Buckpesch-Heberer	Expert - via Adobe*	Germany	No interests declared	
Ailise Carleton	Expert - via Adobe*	Ireland	No interests declared	
Brian Aylward	Expert - via Adobe*	Ireland	No interests declared	
Catherine Byrne	Expert - via Adobe*	Ireland	No interests declared	
Finbarr Leacy	Expert - via Adobe*	Ireland	No interests declared	
Geraldine O`Dea	Expert - via Adobe*	Ireland	No interests declared	
Antonella Isgro	Expert - via Adobe*	Italy	No interests declared	
Danila Renzo	Expert - via Adobe*	Italy	No interests declared	
Odoardo Maria Olimpieri	Expert - via Adobe*	Italy	No interests declared	
Frank Holtkamp	Expert - via Adobe*	Netherlands	No interests declared	
Hinke Johanna van der Woude	Expert - via Adobe*	Netherlands	No interests declared	
Jan Welink	Expert - via Adobe*	Netherlands	No interests declared	
Johannes Theodorus Span	Expert - via Adobe*	Netherlands	No interests declared	
Joost Romme	Expert - via Adobe*	Netherlands	No interests declared	
Lies van Vlijmen	Expert - via Adobe*	Netherlands	No interests declared	
Louise Claessen	Expert - via Adobe*	Netherlands	No interests declared	
Menno van der Elst	Expert - via Adobe*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Nienke Rodenhuis	Expert - via Adobe*	Netherlands	No interests declared	
Sabine Straus	Expert - via Adobe*	Netherlands	No interests declared	
Anja Schiel	Expert - via Adobe*	Norway	No interests declared	
Erlend J Egeland	Expert - via Adobe*	Norway	No interests declared	
Maria Almlof	Expert - via Adobe*	Norway	No interests declared	
Venke Skibeli	Expert - via Adobe*	Norway	No interests declared	
Mario Miguel Coelho da Silva Rosa	Expert - via Adobe*	Portugal	No interests declared	
Susan Webb	Expert - via Adobe*	Spain	No restrictions applicable to this meeting	
Birger Scholz	Expert - via Adobe*	Sweden	No interests declared	
Dariush Mokhtari	Expert - via Adobe*	Sweden	No restrictions applicable to this meeting	
Tom Meyerson Goldschmidt	Expert - via Adobe*	Sweden	no part in discussions, final deliberations and voting as appropriate	somapacitan - EMEA/H/C/005030 Covid-19 mRNA vaccine - H0005735
Meeting run with the help of EMA staff				

*Experts were only evaluated against the product(s) they have been invited to talk about

17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 11)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 12)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 13)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 14.3.1)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 14.2)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 14.3)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

05 January 2021
EMA/CHMP/708333/2020

Annex to 09-12 November 2020 CHMP Minutes

Pre-submission and post-authorisations issues

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for November 2020: **For adoption**	Adopted.

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for November 2020: **For adoption**	Adopted.

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Atriance - nelarabine - EMEA/H/C/000752/S/0051 Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Hans Christian Siersted	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
Brineura - cerliponase alfa - EMEA/H/C/004065/S/0028, Orphan BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 12.11.2020.	Request for Supplementary Information adopted with a specific timetable.
IMVANEX - smallpox vaccine (live modified vaccinia virus Ankara) - EMEA/H/C/002596/S/0054 Bavarian Nordic A/S, Rapporteur: Jan Mueller-	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

Berghaus, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Brigitte Keller-Stanislawski	The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
Mepsevii - vestronidase alfa - EMEA/H/C/004438/S/0017, Orphan Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia Request for Supplementary Information adopted on 12.11.2020.	Request for Supplementary Information adopted with a specific timetable.
Naglazyme - galsulfase - EMEA/H/C/000640/S/0083 BioMarin International Limited, Rapporteur: Fátima Ventura, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Amlodipine-Valsartan Mylan - amlodipine / valsartan - EMEA/H/C/004037/R/0008 Mylan S.A.S, Generic, Generic of Exforge, Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Anette Kirstine Stark Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Descovy - emtricitabine / tenofovir alafenamide - EMEA/H/C/004094/R/0051 Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Ana Sofia Diniz Martins Request for Supplementary Information adopted on 15.10.2020.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Eliquis - apixaban -	Positive Opinion adopted by consensus together

EMEA/H/C/002148/R/0077 Bristol-Myers Squibb / Pfizer EEIG, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Menno van der Elst	with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
Flixabi - infliximab - EMEA/H/C/004020/R/0064 Samsung Bioepis NL B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Galafold - migalastat - EMEA/H/C/004059/R/0027, Orphan Amicus Therapeutics Europe Limited, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
IDELVION - albutrepenonacog alfa - EMEA/H/C/003955/R/0047, Orphan CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Andrea Laslop, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Odefsey - emtricitabine / rilpivirine / tenofovir alafenamide - EMEA/H/C/004156/R/0049 Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Ana Sofia Diniz Martins	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

B.2.3. Renewals of Conditional Marketing Authorisations

OCALIVA - obeticholic acid - EMEA/H/C/004093/R/0023, Orphan Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC	See agenda 9.1 Positive Opinion adopted by consensus together with the CHMP assessment report and

Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 17.09.2020.	translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.
SIRTURO - bedaquiline - EMEA/H/C/002614/R/0040, Orphan Janssen-Cilag International NV, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted. The Marketing Authorisation remains conditional. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

SIGNAL DETECTION PRAC recommendations on signals adopted at the PRAC November 2020 meeting which was held on 26-29 October 2020 PRAC:	
Signal of sarcoidosis Tafinlar, Mekinist - dabrafenib, trametinib, Rapporteur: various, Co-Rapporteur: various, Scope: PRAC recommendation on a variation **Action**: for adoption	Adopted.
Signal of Hepatitis E Imbruvica – ibrutinib, Rapporteur: Filip Josephson, Co-Rapporteur: Sinan B. Sarac, Scope: PRAC recommendation on a variation/review hepatotoxicity in PSUR **Action**: for adoption	Adopted.
PSUR PROCEDURES PRAC recommendations for variation of the terms of the MA at its November 2020 meeting which was held on 26-29 October 2020 PRAC:	
EMEA/H/C/PSUSA/00001210/202004	The CHMP, having considered in accordance with

(emtricitabine / tenofovir disoproxil) CAPS: **Truvada** (EMEA/H/C/000594) (emtricitabine / tenofovir disoproxil), Gilead Sciences Ireland UC, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ana Sofia Diniz Martins, "Period Covered From: 03/04/2019 To: 02/04/2020"	Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 5.1 of the SmPC to amend the information on bone effects. Annex II and the Package leaflet are updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00002892/202003 (tenofovir disoproxil) CAPS: **Tenofovir disoproxil Mylan** (EMEA/H/C/004049) (tenofovir disoproxil), Mylan S.A.S, Rapporteur: Romaldas Mačiulaitis **Tenofovir disoproxil Zentiva** (EMEA/H/C/004120) (tenofovir disoproxil), Zentiva k.s., Rapporteur: John Joseph Borg **Viread** (EMEA/H/C/000419) (tenofovir disoproxil), Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race NAPS: **NAPs** - EUR PRAC Rapporteur: Adrien Inoubli, "Period Covered From: 31/03/2019 To: 31/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisations for the medicinal products containing the above-referred active substance, concerning the following changes: Update of section 4.4 of the SmPC to amend the information on bone effects. Annex II and the Package leaflet are updated accordingly. Update of section 4.6 of SmPC to downgrade the current recommendation for breast-feeding for products indicated in the treatment of HBV. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00003152/202003 (zonisamide) CAPS: **Zonegran** (EMEA/H/C/000577) (zonisamide), Eisai GmbH, Rapporteur: Peter Kiely NAPS: **NAPs** - EU PRAC Rapporteur: Rhea Fitzgerald, "From: 01/04/2019 To: 31/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning on hyperammonaemia. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00009147/202003 (exenatide) CAPS: **Bydureon** (EMEA/H/C/002020) (exenatide), AstraZeneca AB, Rapporteur: Kristina Dunder **BYETTA** (EMEA/H/C/000698) (exenatide), AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "Period Covered From: 01/04/2019 To: 31/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add 'delayed gastric emptying' as a new ADR. The Package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00009200/202003 (ipilimumab) CAPS: **Yervoy** (EMEA/H/C/002213) (ipilimumab), Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Period Covered From: 24/03/2019 To: 24/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add solid organ transplant rejection with a frequency not known and to amend the information on the adverse reaction haemophagocytic lymphohistiocytosis. The Package leaflet is updated accordingly. The MAH took also the occasion to include some editorial changes in the package leaflet. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010061/202004 (alogliptin, alogliptin / metformin, alogliptin / pioglitazone) CAPS: **Incresync** (EMEA/H/C/002178) (alogliptin / pioglitazone), Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege **Vipdomet** (EMEA/H/C/002654) (alogliptin / metformin / metformin hydrochloride), Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege **Vipidia** (EMEA/H/C/002182) (alogliptin), Takeda Pharma A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, "From: 14/04/2019 To: 14/04/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to add a warning on post-marketing reports of bullous pemphigoid in patients taking DPP-4 inhibitors including alogliptin, and if bullous pemphigoid is suspected alogliptin should be discontinued. Update of section 4.8 of the SmPC to include the new adverse drug reactions 'Bullous pemphigoid' and 'Interstitial nephritis' (with frequency unknown). The package leaflet is updated

	accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010077/202003 (canagliflozin, canagliflozin / metformin) CAPS: **Invokana** (EMEA/H/C/002649) (canagliflozin), Janssen-Cilag International NV, Rapporteur: Martina Weise **Vokanamet** (EMEA/H/C/002656) (canagliflozin / metformin), Janssen-Cilag International NV, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "Period Covered From: 29/03/2019 To: 28/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): - Update of section 4.8 of the SmPC to reflect the post-marketing information on treatment interruption in case of UTI. - Update of section 4.4 to add a warning on UTI. The package leaflet section 2 is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010319/202004 (nintedanib (respiratory indication)) CAPS: **OFEV** (EMEA/H/C/003821) (nintedanib), Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, PRAC Rapporteur: Nikica Mirošević Skvrce, "From: 15/10/2019 To: 15/04/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product, concerning the following change: Update of section 4.4 of SmPC to add a warning on the risk of ischaemic colitis, and corresponding update of PL. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010645/202003 (dupilumab) CAPS: **Dupixent** (EMEA/H/C/004390) (dupilumab), sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Kimmo Jaakkola, "From: 28/09/2019 To: 28/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reactions Keratitis and Ulcerative keratitis with a frequency 'Uncommon' in AD and Keratitis with frequency 'Rare' for Asthma are proposed. Respective warning is proposed to be added in the SmPC section 4.4.

	The package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010662/202003 (ocrelizumab) CAPS: **Ocrevus** (EMEA/H/C/004043) (ocrelizumab), Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Period Covered From: 27/03/2019 To: 27/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4 and 4.8 of the SmPC to add the adverse reaction late onset of neutropenia with a frequency not known. The package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
EMEA/H/C/PSUSA/00010818/202003 (siponimod) CAPS: **Mayzent** (EMEA/H/C/004712) (siponimod), Novartis Europharm Limited, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Maria del Pilar Rayon, "Period Covered From: 25/09/2019 To: 25/03/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Addition of Basal Cell Carcinoma in section 4.8 of the SmPC. The warning about cutaneous neoplasms is updated with the new information regarding the increase of the cases with long–term exposure. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

B.4. EPARs / WPARs

Fintepla - fenfluramine - EMEA/H/C/003933, Orphan Zogenix ROI Limited, treatment of seizures associated with Dravet syndrome in children aged 2 years to 17 years and adults., Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Isturisa – osilodrostat - EMEA/H/C/004821 Recordati Rare Diseases; indicated for the treatment of endogenous Cushing's syndrome in	For information only. Comments can be sent to the PL in case necessary.

adults. New active substance (Article 8(3) of Directive No 2001/83/EC) **2nd Corrected EPAR**	
Lenalidomide Mylan - lenalidomide - EMEA/H/C/005306 Mylan Ireland Limited, treatment of multiple myeloma, Generic, Generic of Revlimid, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Leqvio - inclisiran - EMEA/H/C/005333 Novartis Europharm Limited, treatment for primary hypercholesterolaemia or mixed dyslipidaemia, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Libmeldy - autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene - EMEA/H/C/005321, Orphan, ATMP Orchard Therapeutics (Netherlands) BV, treatment of metachromatic leukodystrophy (MLD), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Oxlumo - lumasiran - EMEA/H/C/005040, Orphan Alnylam Netherlands B.V., primary hyperoxaluria type 1 (PH1), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Palforzia - defatted powder of arachis hypogaea l., semen (peanuts) - EMEA/H/C/004917 Aimmune Therapeutics Ireland Limited, desensitization of children and adolescents to peanut allergy, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Puldysa - idebenone - EMEA/H/C/005123, Orphan Santhera Pharmaceuticals (Deutschland) GmbH, treatment of respiratory dysfunction in patients with Duchenne muscular dystrophy (DMD) not using glucocorticoids, Hybrid application (Article 10(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.

Rekambys - rilpivirine - EMEA/H/C/005060 Janssen-Cilag International N.V., treatment of human of human immunodeficiency virus type 1 (HIV-1), Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Roctavian (WD) - valoctocogene roxaparvovec - EMEA/H/C/004749, Orphan, ATMP BioMarin International Limited, treatment of haemophilia A, New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - EMEA/H/C/005102, Orphan, ATMP Kite Pharma EU B.V., treatment of adult patients with relapsed or refractory Mantle cell lymphoma (MCL), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
TRIXEO AEROSPHERE - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide - EMEA/H/C/004983 AstraZeneca AB, maintenance treatment in adult patients with moderate to very severe chronic obstructive pulmonary disease (COPD), Fixed combination application (Article 10b of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Udenyca - pegfilgrastim - EMEA/H/C/004413 ERA Consulting GmbH; treatment of neutropenia, Similar biological application (Article 10(4) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
Uplizna (WD) - inebilizumab - EMEA/H/C/005412 Viela Bio, Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorders(NMOSD)., New active substance (Article 8(3) of Directive No 2001/83/EC) **WPAR**	For information only. Comments can be sent to the PL in case necessary.
VOCABRIA - cabotegravir - EMEA/H/C/004976	For information only. Comments can be sent to the PL in case necessary.

ViiV Healthcare B.V., treatment of Human Immunodeficiency Virus type 1 (HIV-1), New active substance (Article 8(3) of Directive No 2001/83/EC)	

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Benlysta - belimumab - EMEA/H/C/002015/II/0084 GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder Opinion adopted on 06.11.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Betaferon - interferon beta-1b - EMEA/H/C/000081/II/0129 Bayer AG, Rapporteur: Martina Weise Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
CRYSVITA - burosumab - EMEA/H/C/004275/II/0017, Orphan Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 12.11.2020, 10.09.2020.	Request for supplementary information adopted with a specific timetable.
Darzalex - daratumumab - EMEA/H/C/004077/II/0040, Orphan Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac Request for Supplementary Information adopted on 06.11.2020.	Request for supplementary information adopted with a specific timetable.
Extavia - interferon beta-1b - EMEA/H/C/000933/II/0102 Novartis Europharm Limited, Informed Consent of Betaferon, Rapporteur: Martina Weise Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0017 Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 12.11.2020. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 08.10.2020.	
Gardasil - human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - EMEA/H/C/000703/II/0089/G MSD Vaccins, Rapporteur: Kristina Dunder Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Gardasil 9 - human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0043/G MSD Vaccins, Rapporteur: Kristina Dunder Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Herzuma - trastuzumab - EMEA/H/C/002575/II/0031 Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Hizentra - human normal immunoglobulin - EMEA/H/C/002127/II/0117 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Imraldi - adalimumab - EMEA/H/C/004279/II/0037/G Samsung Bioepis NL B.V., Rapporteur: Outi Mäki-Ikola Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Kevzara - sarilumab - EMEA/H/C/004254/II/0024/G sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
Lokelma - sodium zirconium cyclosilicate - EMEA/H/C/004029/II/0021/G AstraZeneca AB, Rapporteur: Romaldas Mačiulaitis Request for Supplementary Information adopted on 06.11.2020.	Request for supplementary information adopted with a specific timetable.

Miglustat Gen.Orph - miglustat - EMEA/H/C/004366/II/0013 Gen.Orph, Generic, Generic of Zavesca, Rapporteur: Milena Stain Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Mimpara - cinacalcet - EMEA/H/C/000570/II/0068 Amgen Europe B.V., Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0082 Genzyme Europe BV, Co-Rapporteur: Karin Janssen van Doorn Opinion adopted on 12.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
NovoMix - insulin aspart - EMEA/H/C/000308/II/0105 Novo Nordisk A/S, Rapporteur: Kristina Dunder Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 10.09.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0109/G Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 22.10.2020.	Request for supplementary information adopted with a specific timetable.
Nucala - mepolizumab - EMEA/H/C/003860/II/0033 GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Nulojix - belatacept - EMEA/H/C/002098/II/0065/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson"B.I.a.2.c - B.I.b.1.c – B.I.b.2.b – Request for Supplementary Information adopted on 12.11.2020, 12.03.2020.	See agenda 9.1 Request for supplementary information adopted with a specific timetable.
Nulojix - belatacept - EMEA/H/C/002098/II/0072/G Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 22.10.2020.	
Remsima - infliximab - EMEA/H/C/002576/II/0093/G Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Opinion adopted on 22.10.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Repatha - evolocumab - EMEA/H/C/003766/II/0044 Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 29.10.2020, 10.09.2020.	Request for supplementary information adopted with a specific timetable.
Rilutek - riluzole - EMEA/H/C/000109/II/0065 Sanofi Mature IP, Rapporteur: Kirstine Moll Harboe Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ritonavir Mylan - ritonavir - EMEA/H/C/004549/II/0007/G Mylan S.A.S, Generic, Generic of Norvir, Rapporteur: John Joseph Borg Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 01.10.2020, 16.07.2020, 17.04.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Rybelsus - semaglutide - EMEA/H/C/004953/II/0006 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 12.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Rybelsus - semaglutide - EMEA/H/C/004953/II/0007 Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Sancuso - granisetron - EMEA/H/C/002296/II/0058 Kyowa Kirin Holdings B.V., Rapporteur: Simona Stankeviciute Request for Supplementary Information adopted on 12.11.2020, 03.09.2020.	Request for supplementary information adopted with a specific timetable.
Simponi - golimumab - EMEA/H/C/000992/II/0093	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP

Janssen Biologics B.V., Rapporteur: Kristina Dunder Opinion adopted on 22.10.2020.	Members were in agreement with the CHMP recommendation.
Simponi - golimumab - EMEA/H/C/000992/II/0095 Janssen Biologics B.V., Rapporteur: Kristina Dunder Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 10.09.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Trepulmix - treprostinil sodium - EMEA/H/C/005207/II/0002/G, Orphan SciPharm Sarl, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Trulicity - dulaglutide - EMEA/H/C/002825/II/0053/G Eli Lilly Nederland B.V., Rapporteur: Martina Weise Opinion adopted on 22.10.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Trulicity - dulaglutide - EMEA/H/C/002825/II/0054 Eli Lilly Nederland B.V., Rapporteur: Martina Weise Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
Zavicefta - ceftazidime / avibactam - EMEA/H/C/004027/II/0023/G Pfizer Ireland Pharmaceuticals, Rapporteur: Bjorg Bolstad Request for Supplementary Information adopted on 06.11.2020, 01.10.2020.	Request for supplementary information adopted with a specific timetable.
WS1870/G **Entresto-EMEA/H/C/004062/WS1870/0033/G** **Neparvis-EMEA/H/C/004343/WS1870/0030/G** Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 23.07.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1926/G **Hexacima-EMEA/H/C/002702/WS1926/0106/G**	Request for supplementary information adopted with a specific timetable.

Hexaxim-EMEA/H/W/002495/WS1926/0111/G **Hexyon-EMEA/H/C/002796/WS1926/0110/G** Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 12.11.2020.	

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Betaferon - interferon beta-1b - EMEA/H/C/000081/II/0130 Bayer AG, Rapporteur: Martina Weise, "C.I.4 Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on Thrombotic Microangiopathy by adding information about Haemolytic anaemia and add Haemolytic anaemia to the list of adverse drug reactions (ADRs) with frequency unknown based on the cumulative review of available data including case reports from post-marketing surveillance and scientific literature. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/II/0034 Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, "Update of section 4.8 of the SmPC in order to add the Stevens-Johnson Syndrome (SJS) to the list of adverse drug reactions (ADRs) with frequency "rare" based on an internal cumulative safety review performed by the company and prompted by a spontaneous case report of a HIV patient who experienced SJS during treatment with Biktarvy. The Package Leaflet is updated accordingly." Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
ELOCTA - efmoroctocog alfa - EMEA/H/C/003964/II/0039 Swedish Orphan Biovitrum AB (publ), Rapporteur: Jan Mueller-Berghaus, "Update of sections 4.2, 4.8 and 5.1 of the SmPC to include the results of study 997HA306 in previously untreated patients which have previously been	Request for supplementary information adopted with a specific timetable.

assessed as an Article 46 paediatric submission and renewal (EMEA/H/C/003964/R/0036).” Request for Supplementary Information adopted on 12.11.2020, 10.09.2020.	
Erleada - apalutamide - EMEA/H/C/004452/II/0007/G Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, “Update of section 4.8 of the SmPC in order to add toxic epidermal necrolysis and decreased appetite to the list of adverse drug reactions (ADRs) with frequency 'not known' and 'very common' respectively based on cumulative safety reviews; the Package Leaflet is updated accordingly.” Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 10.09.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Ervebo - recombinant vesicular stomatitis virus - Zaire ebolavirus vaccine (live) - EMEA/H/C/004554/II/0008/G Merck Sharp & Dohme B.V., Rapporteur: Christophe Focke, “(Type IB) B.II.b.3.z (Type II) C.I.11.b - Update to Annex II to delete Specific Obligations 2 and 4 and conversion to marketing authorisation not subject to specific obligations. In addition, the MAH is updating section 5.1 of the SmPC and section 6 of the Package Leaflet to delete the conditional marketing authorisation details. The MAH has taken the opportunity to propose a progress report to be provided following a Post-Authorisation Measure ” Opinion adopted on 12.11.2020.	See 9.1 Positive Opinion adopted by consensus on 12.11.2020. In addition, the CHMP, having considered the application as set out in the appended assessment report and on the basis of the evidence of compliance with the specific obligations submitted by the marketing authorisation holder, was of the opinion that the risk-benefit balance of the above mentioned medicinal product remains favourable. As all specific obligations laid down in Annex II have been fulfilled, pursuant to Article 7 of Regulation (EC) No 507/2006, the CHMP recommended by consensus the granting of a Marketing Authorisation in accordance with Article 14(1) of Regulation (EC) No 726/2004 for the above mentioned medicinal product, pursuant the Article 14-(8) of Regulation (EC) No 726/2004. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Extavia - interferon beta-1b - EMEA/H/C/000933/II/0103 Novartis Europharm Limited, Informed Consent of Betaferon, Rapporteur: Martina Weise, “Type II variation to update SmPC section 4.8 with the addition of haemolytic anaemia (HA) as an adverse drug reaction of 'unknown' frequency' based on cumulative review of available data including case reports from post-marketing	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

surveillance and scientific literature. Section 4.4 of the SmPC and corresponding sections in the PL are updated with a precautionary statement, considering the importance of drug discontinuation for patients with Thrombotic Microangiopathy TMA/HA, to reflect the most recent post-marketing experience." Opinion adopted on 29.10.2020.	
Eylea - aflibercept - EMEA/H/C/002392/II/0066 Bayer AG, Rapporteur: Alexandre Moreau, "Submission of final CSR for study 17514 (CENTERA). This is an international, multi-center, prospective, interventional, single-arm, open- label, phase 4 study on the efficacy, durability, posology and safety of the T&E regimen in subjects with macular edema secondary to CRVO." Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
Gardasil - human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - EMEA/H/C/000703/II/0087 MSD Vaccins, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update the information of the duration of immunity following a 2-dose schedule of Gardasil based on the results from extension Protocol V501-167; this was a randomized clinical trial that assessed the immunogenicity of a 2 dose schedule of the qHPV in adolescents 9 to 13 years of age compared to a 3-dose schedule in young women 16 to 26 years of age. In addition, the MAH is taking the opportunity to update the product information in line with the Excipients guideline (SANTE-2017-11668) and the Guideline on quality aspects included in the product information for vaccines for human use (EMA/CHMP/BWP/133540/2017). Furthermore, the PI is being brought in line with the latest QRD template (version 10.1) and some minor editorial changes regarding the nomenclature for excipients have been implemented." Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 10.09.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Gardasil 9 - human papillomavirus vaccine	Request for supplementary information adopted

[types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) - EMEA/H/C/003852/II/0040 MSD Vaccins, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in relation to the post-marketing safety experience information, currently based on the post-marketing safety experience for the quadrivalent HPV vaccine, based on 4 years of post-marketing experience of the 9vHPV vaccine. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to update the wording regarding sodium according to the Guideline on quality aspects included in the product information for vaccines for human use EMA/CHMP/BWP/133540/2017 and to implement an editorial change in sections 5.1 and 9 of the SmPC, and the package leaflet." Request for Supplementary Information adopted on 06.11.2020, 10.09.2020.	with a specific timetable.
Imnovid - pomalidomide - EMEA/H/C/002682/II/0038, Orphan Celgene Europe BV, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC with information from a paediatric study in patients aged 4 to 18 years with recurrent or progressive high-grade glioma, medulloblastoma, ependymoma or diffuse intrinsic pontine glioma (DIPG) with primary location in the CNS." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0015 Bayer AG, Rapporteur: Kirstine Moll Harboe, "Update of sections 4.8 and 5.1 of the SmPC to reflect the final study report of the long-term extension study 15912 (PROTECT Kids) in children. This extension study is a category 3 study of the Jivi RMP. The MAH took the opportunity to update the list of local representatives in the PIL." Opinion adopted on 12.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Lorviqua - lorlatinib - EMEA/H/C/004646/II/0008 Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.4 and 4.8 to	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

include the new term "Psychotic effects" as an adverse drug reaction (ADR) based on the cumulative review of the data available through Clinical Databases and Safety Database. The package leaflet has been updated accordingly." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020.	
LUTATHERA - lutetium (177Lu) oxodotreotide - EMEA/H/C/004123/II/0022, Orphan Advanced Accelerator Applications, Rapporteur: Janet Koenig, "Update of sections 4.2, 4.4, 4.5, 4.6 and 4.8 of the SmPC in order to introduce structural changes in the dosing and administration and warnings and precautions section, include clarifications in the pregnancy and overdose sections, update instructions for use based on end user feedback and update of amino acid solution information based on review and approval of LysaKare; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include correction of typographical errors and editorial changes in the PI in line with the latest QRD template version 10.1." Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0081 Genzyme Europe BV, Rapporteur: Alexandre Moreau, "Update of section 5.1 of the SmPC on long term clinical effects of alglucosidase alfa based on the review of published scientific literature. In addition, the MAH took the opportunity to update the Product Information to mention the change on contact details of local representatives for Italy and Malta and to add traceability statement as per QRD template version 10.1." Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 25.06.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
OFEV - nintedanib - EMEA/H/C/003821/II/0033 Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, "Update of SmPC section 5.1. to include additional clinical	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

information from an open-label extension trial 1199.33 (INPULSIS-ON) of the pivotal phase III, randomised, double-blind, placebo-controlled studies with identical design (INPULSIS-1 (1199.32) and INPULSIS-2 (1199.34)). This trial provides safety and efficacy data up to 192 weeks." Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 16.07.2020.	
OFEV - nintedanib - EMEA/H/C/003821/II/0034 Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, "Update of section 5.1 of the SmPC to include results of a double-blind, randomised, parallel-group trial to evaluate the efficacy and safety of Ofev co-administered with oral sildenafil, compared to treatment with Ofev alone (INSTAGE Trial)." Request for Supplementary Information adopted on 22.10.2020, 16.07.2020.	Request for supplementary information adopted with a specific timetable.
Praluent - alirocumab - EMEA/H/C/003882/II/0059 sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to change posology recommendations, the undesirable effects section and pharmacokinetic and pharmacodynamic sections with information on paediatric population, based on final results from study EFC14660, a category 3 open-label study in the RMP, to evaluate the efficacy and safety of alirocumab in children and adolescents with homozygous familial hypercholesterolemia; the Package Leaflet is updated accordingly." Opinion adopted on 12.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Repatha - evolocumab - EMEA/H/C/003766/II/0043 Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "C.I.4, Update of section 5.1 of the SmPC based on final results from study 20167869 (EVOPACS). It was a randomised, double-blind, placebo-controlled, multicenter study assessing the superiority of evolocumab vs. placebo administered during the acute phase of ACS (within 72 hours)." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 23.07.2020.	
Somavert - pegvisomant - EMEA/H/C/000409/II/0097 Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Update of sections 4.4, 4.6 and 5.3 of the SmPC in order to add a new warning on acromegaly control and adjustment of doses during pregnancy, include information on use during pregnancy and effects on fertility, as well as an update on the effects of the drug product on the early embryonic development and embryo-foetal development in pregnant rabbits, following international regulatory procedure outcomes and literature review. The MAH took the opportunity to make editorial changes to the Package Leaflet." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Spravato - esketamine - EMEA/H/C/004535/II/0004 Janssen-Cilag International N.V., Rapporteur: Martina Weise, "to update the Spravato Product Information at section 4.2 to replace the current dosing recommendation in patients with Japanese ancestry with a statement that efficacy of Spravato in Japanese patients has not been established to date. This dosing recommendation is supported by the completed Phase 2 study 54135419TRD2005" Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Tresiba - insulin degludec - EMEA/H/C/002498/II/0047 Novo Nordisk A/S, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update the description of day-to-day variability in glucose-lowering effect further to assessment of post-authorisation measure LEG013. In addition, the MAH took the opportunity to make editorial corrections in section 5.2 of the SmPC." Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 10.09.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Tysabri - natalizumab - EMEA/H/C/000603/II/0117 Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, "C.I.4 Update of section 5.2 of the SmPC in order to update pharmacokinetic	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

information based on an updated PK analysis from 11 studies (both IV and SC administration) and data with serial PK sampling as measured by an industry standard assay." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 28.05.2020.	
Veklury - remdesivir - EMEA/H/C/005622/II/0012 Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Submission of the final D28 mortality data by ordinal scale categories of study COUS-540-5776 (NIAID-ACTT1), listed as a Specific Obligation in the Annex II of the Product Information, in order to confirm the efficacy and safety of remdesivir in patients on Invasive Mechanical Ventilation and Extracorporeal Membrane Oxygenation (IMV/ECMO). In addition, the MAH discuss the potential imbalance in the use of corticosteroids and effect modification in study CO-US-540-5776. As a consequence, Annex II is updated accordingly." Request for Supplementary Information adopted on 12.11.2020.	See agenda 9.1 Request for supplementary information adopted with a specific timetable.
Venclyxto - venetoclax - EMEA/H/C/004106/II/0031 AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "to update venetoclax SmPC wording regarding tumour lysis syndrome (TLS) prophylaxis and management following an update to the Company Core Data Sheet (CCDS) as result of a medical safety assessment conducted on TLS post-marketing reports. The proposed changes to the SmPC include sections 4.2 and 4.4: - Section 4.2: A more prescriptive table which replaces the text around the risk assessment, prophylaxis and monitoring measures based on the level of tumour burden. In addition, the text on the recommended dose modifications for toxicities is replaced by a table format for clarity. - Section 4.4: the text is revised to emphasise the fact that TLS occur in all patients and requires adequate risk assessment that considers comorbidities, particularly renal impairment, and other risk factors such as splenomegaly." Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 12.11.2020.	
Votrient - pazopanib - EMEA/H/C/001141/II/0059 Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, "To update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on results from studies 2012-001306-20 (ADVL0815 / PZP114411) and study 2013-003595-12 (ADVL1322 / VEG116731 / PZP034X2203) listed in the agreed PIP; these are a phase 1 clinical trial of single-agent pazopanib in children with a relapsed or refractory solid (including CNS) tumour, and a therapeutic-exploratory (phase 2) clinical trials of single-agent pazopanib in children (including adolescents) and young adults with a refractory tumour." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 15.10.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xagrid - anagrelide - EMEA/H/C/000480/II/0089 Shire Pharmaceuticals Ireland Limited, Rapporteur: Alexandre Moreau, "C.I.4, Update of sections 4.5. and 5.2 of the SmPC in order to add drug-drug interaction information with omeprazole, and update pharmacokinetics, based on final results from clinical study SPD-422-113 a Drug-Drug interaction (DDI) study with Xagrid (anagrelide hydrochloride) assessing the effect of multiple doses omeprazole on anagrelide and 3-OH anagrelide exposure. The study was agreed as a commitment in variation EMEA/H/C/000480/II/0075" Opinion adopted on 06.11.2020. Request for Supplementary Information adopted on 04.09.2020, 05.06.2020.	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Xarelto - rivaroxaban - EMEA/H/C/000944/II/0081 Bayer AG, Rapporteur: Kristina Dunder, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC following the final results from the VOYAGER PAD study, a multicentre, randomised, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization	Request for supplementary information adopted with a specific timetable.

procedures. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 12.11.2020.	
XOSPATA - gilteritinib - EMEA/H/C/004752/II/0003, Orphan Astellas Pharma Europe B.V., Rapporteur: Bjorg Bolstad, "C.I.4 Update of section 5.2 of the SmPC in order to update information about Transporter drug-drug interactions based on final results from in vitro transporter studies identified as recommendations by CHMP (REC003) during the initial approval. In addition, the MAH took the opportunity to perform minor corrections and editorial changes in the PI." Request for Supplementary Information adopted on 29.10.2020, 03.09.2020.	Request for supplementary information adopted with a specific timetable.
WS1891/G **CONTROLOC Control-EMEA/H/C/001097/ WS1891/0036/G** **PANTOLOC Control-EMEA/H/C/001100/ WS1891/0041/G** **PANTOZOL Control-EMEA/H/C/001013/ WS1891/0038/G** **SOMAC Control-EMEA/H/C/001098/ WS1891/0037/G** Takeda GmbH, Lead Rapporteur: Simona Stankeviciute, "Group of variations 1. To update sections 4.4 and 4.8 of the SmPC in order to add warnings related to Hypocalcaemia/Hypokalaemia based on the Signal Evaluation Reports; FORM-0003948 - Takeda Signal Evaluation Report, Products Dexlansoprazole, Lansoprazole and Pantoprazole, Signal: Hypocalcemia, dated February 13, 2020. The Package Leaflet is updated accordingly. 2. To update section 4.8 of the SmPC in order to add DRESS ADR based on the Signal Evaluation Reports; FORM-0003948 - Takeda Signal Evaluation Report, Products Dexlansoprazole, Lansoprazole and Pantoprazole, Signal: Drug reaction with eosinophilia and systemic symptoms (DRESS) dated January 29, 2020. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the last QRD template (version 10.1), to update the list of local representatives and implement to editorial corrections to the PI."	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 29.10.2020.	
WS1893 **Blitzima-EMEA/H/C/004723/WS1893/0034** **Ritemvia-EMEA/H/C/004725/WS1893/0034** **Truxima-EMEA/H/C/004112/WS1893/0037** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, Lead PRAC Rapporteur: Hans Christian Siersted, "To provide CT-P10 3.4 final CSR along with the updated RMP (version 10.1) in compliance with the post-authorisation measure. CT-P10 3.4 was a Phase 3, randomised, parallel-group, active-controlled, double-blind study to compare efficacy and safety between CT-P10 and Rituxan in patients with LTBFL. Study CTP10 3.4 was designed to demonstrate similarity of efficacy of CT-P10 to Rituxan in patients with LTBFL. The patients were randomised in a 1:1 ratio in a double-blinded fashion." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.3. CHMP-PRAC assessed procedures

Imfinzi - durvalumab - EMEA/H/C/004771/II/0023 AstraZeneca AB, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: David Olsen, "Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen of 1500 mg every 4 weeks (Q4W) for the approved indication of the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy. The RMP version 4.1 has also been submitted." Request for Supplementary Information adopted on 12.11.2020, 15.10.2020.	Request for supplementary information adopted with a specific timetable.
NINLARO - ixazomib - EMEA/H/C/003844/II/0022, Orphan Takeda Pharma A/S, Rapporteur: Armando	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

Genazzani, PRAC Rapporteur: Annika Folin, "To update section 4.8 undesirable effects of the Ninlaro (Ixazomib) Summary of Product Characteristics (SmPC) following the adoption of the CHMP opinion in 25 June 2020 on PSUR assessment procedure EMEA/H/C/PSUSA/00010535/201911. Consequently, ADRs: acute febrile neutrophilic dermatosis, Stevens-Johnson syndrome, transverse myelitis, posterior reversible encephalopathy disorders and tumour lysis syndrome have been assigned frequency rare." Opinion adopted on 12.11.2020.	recommendation.
Ocrevus - ocrelizumab - EMEA/H/C/004043/II/0021 Roche Registration GmbH, Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.4 in order to include the term 'anaphylaxis' among the possible symptoms of infusion-related reactions (IRRs), following an analysis of cases retrieved by anaphylactic reaction MedDRA narrow SMQ. The MAH took the opportunity to update Annex II.C and D in line with the QRD template. The RMP version 6.0 has been submitted." Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
Rekovelle - follitropin delta - EMEA/H/C/003994/II/0022 Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst, "Update of section 4.2 of the SmPC in order to introduce a new anti-Müllerian hormone (AMH) assay to determine the dose of follitropin delta, following an agreed recommendation. In consequence, RMP version 5.0 was submitted and updated in line with GPV Module V rev.2. The MAH took the opportunity to amend section 4.4. of the SmPC with traceability information, to bring the PI in line with the latest QRD template version 10.1." Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
Rubraca - rucaparib - EMEA/H/C/004272/II/0020 Clovis Oncology Ireland Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin, "Update of sections 4.2 and 5.2 of the SmPC in order to update the information on the	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

use of rucaparib in patients with hepatic impairment based on final results from Part I of study CO-338-078 listed as a category 3 study in the RMP; this is a phase 1, open- label, parallel group study to determine the pharmacokinetics, safety and tolerability of rucaparib in patients with an advanced solid tumour and either moderate hepatic impairment or normal hepatic function; the Package Leaflet is updated accordingly. The RMP version 4.2 has also been submitted. In addition, the MAH took the opportunity to make minor corrections in the SmPC, to update the list of local representatives in the Package Leaflet, and to bring the PI in line with the latest QRD template version 10.1 and excipient guideline." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020.	
Somavert - pegvisomant - EMEA/H/C/000409/II/0098/G Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Adrien Inoubli, "Variation to update the Risk Management Plan following assessment of the final results of ACROSTUDY, a multicenter, Post Authorisation Safety Study (PASS) of Somavert therapy in patients with acromegaly (procedure number EMEA/H/C/000409/II/0089), grouped with variation to update of section 4.4 of the SmPC to remove the warning on growth hormone secreting tumours, consequential to the removal of pituitary tumour growth as a potential risk from the RMP. The RMP version 2.0 has been submitted and the MAH took the opportunity to update it as per the revised version of the GVP Module V Risk Management Systems, revision 2. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
Vargatef - nintedanib - EMEA/H/C/002569/II/0035/G Boehringer Ingelheim International GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Agni Kapou, "Update of sections 4.5, 4.6 and 5.2 of the SmPC to reflect the results of study 1199-0340 conducted in female patients with Systemic Sclerosis associated Interstitial Lung disease (SSc-ILD), to investigate a potential	Request for supplementary information adopted with a specific timetable.

interaction between nintedanib and the oral contraceptive Microgynon, a combination of ethynilestradiol and levonorgestrel. Update of sections 4.3 and 4.6 of the SmPC to introduce a new contraindication of pregnancy for Vargatef treatment. This follows the same update for Ofev (nintedanib) introduced in the context of procedure EMEA/H/C/3821/II/0026 and the request from the PRAC in the context of procedure EMEA/H/C/PSUSA/00010318/201910 to consider a similar update for Vargatef. The Package Leaflet is updated accordingly. The RMP version 7.0 has also been submitted reflecting the consequential changes to the submission of study 1199-0340, changes submitted further to the agreement on the same changes implemented for Ofev and other changes requested by the PRAC." Request for Supplementary Information adopted on 12.11.2020.	
WS1664 **Keppra-EMEA/H/C/000277/WS1664/0187** UCB Pharma S.A., Lead Rapporteur: Karin Janssen van Doorn, Lead PRAC Rapporteur: Laurence de Fays, "Update of section 4.2 of the SmPC to recommend the same dosing for monotherapy and adjunctive therapy based on data from modelling and simulation project. The Package Leaflet is updated accordingly. The RMP version 9.2 has also been submitted. The MAH took the opportunity to move Braille to another box section and to review and adapt the German PI according to the current QRD template." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020, 23.07.2020, 30.04.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1830 **Entresto-EMEA/H/C/004062/WS1830/0032** **Neparvis-EMEA/H/C/004343/WS1830/0029** Novartis Europharm Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Anette Kirstine Stark, "C.I.13: Submission of the final report from study CLCZ696D2301 (PARAGON HF) listed as a category 3 study in the RMP. The intention of this submission is to fulfil post-authorisation measure (MEA 003) to evaluate cognitive	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

function in this interventional multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction. The RMP version 2.0 has also been submitted." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 25.06.2020.	
WS1915 **Epclusa-EMEA/H/C/004210/WS1915/0051** **Harvoni-EMEA/H/C/003850/WS1915/0091** **Vosevi-EMEA/H/C/004350/WS1915/0043** Gilead Sciences Ireland UC, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the final report from study GS-US-248-0123, listed as a category 3 study in the RMP. This is a long-term observational follow-up registry of subjects who did not achieve sustained virologic response in Gilead-sponsored trials in subjects with chronic hepatitis C infection. The RMPs have also been submitted for each of the products in this work-sharing procedure (Harvoni v8.0, Epclusa v7.0 and Vosevi v4.0)." Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.4. PRAC assessed procedures

PRAC Led **Betmiga - mirabegron - EMEA/H/C/002388/II/0033** Astellas Pharma Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Final study report of the PASS Study 178-CL-114 – An evaluation of Cardiovascular Events in Users of Mirabegron and Other Treatments for Overactive Bladder." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 11.06.2020, 13.02.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Bronchitol - mannitol - EMEA/H/C/001252/II/0042, Orphan**	Request for supplementary information adopted with a specific timetable.

Pharmaxis Europe Limited, PRAC Rapporteur: Adrien Inoubli, "Submission of an updated RMP version 9.0 based on the new RMP template (GVP module V, revision 2). The MAH took the opportunity to review the safety information contained in the RMP and proposed to reclassify "Cough" from an important potential risk to an important identified risk; to remove the important identified risks "Bronchospasm during and after the initiation dose assessment" and "Bronchospasm during long term use"; to remove the important potential risk "Cough-related sequelae"; "Off label use in non-CF bronchiectasis" "Off label use in paediatric/adolescent CF patients (aged 6-17 years)"; "Administration of Bronchitol via the wrong inhaler device"; "Starting Bronchitol treatment without completing the full BIDA dose"; to remove the missing information "Patients requiring home oxygen or needing assisted ventilation"; "Children <6 years of age"; "Pregnancy and lactation"; "Risks associated with long-term use" from the list of safety concerns; to add "Increased risk of respiratory or systemic infection" as an important potential risk combining, replacing "Pulmonary abscess on continued use", "Septicaemia on continued use", "Increased risk of bacteria sputum identified or infections with extended use of Bronchitol", and "Microbial infection via a contaminated inhaler device", previously classified as important potential risks, which are proposed to be removed from the list of safety concerns. In addition, following the completion of UK CF Registry study (cat 2, PASS) EMEA/H/C/001252/SW/0036, this study has been removed from the RMP, and clinical trial and post-marketing exposure and safety information have been updated to reflect the results of the DPM-CF-303 study previously assessed in EMEA/H/C/001252/II/0034 and the information presented in the latest PSUR #9 (PSUSA/ 0009226/201904)." Request for Supplementary Information adopted on 29.10.2020.	
PRAC Led **Ceplene - histamine dihydrochloride - EMEA/H/C/000796/II/0040** Noventia Pharma S.r.l., Rapporteur: Jayne Crowe, PRAC Rapporteur: Rhea Fitzgerald,	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC-CHMP liaison: Jayne Crowe, "Submission of an updated RMP version 8.1 in order to include the information about the termination of the non-interventional study (NIS) of category 3 Ceplene-3290 and of the PAES Ceplene Cohort Study 3306. -RMP has been adapted to the new RMP template (GVP V rev.2, mandatory since 31 March 2018). -The safety concerns (Part II Modules SVII and SVIII, Part V, Part VI) have been changed. A new important potential risk, named "Drug effect decreased as a consequence of drug interaction", has been added to the list of safety concerns. -Part III and Part IV have been updated to include information about the termination of the non-interventional study (NIS) of category 3 Ceplene-3290 and of the PAES Ceplene Cohort Study 3306. -updated information about the other ongoing studies included in the Pharmacovigilance Plan, "Ceplene-3292" and "Ceplene-3298", have been included in Part III and related parts/modules. -Details about the Marketing Authorisation Holder have been updated accordingly upon implementation of transfer from previous Marketing Authorisation Holder, Meda AB, (positive decision received 08 December 2017)" Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 17.04.2020.	
PRAC Led **Forsteo - teriparatide - EMEA/H/C/000425/II/0054** Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "submission of the concluding report of the European Union (EU) component of the post-authorisation safety study (PASS): Study B3D-MC-GHBX(2.1) of Forsteo (teriparatide)." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 09.07.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Jinarc - tolvaptan - EMEA/H/C/002788/II/0029** Otsuka Pharmaceutical Netherlands B.V., Rapporteur: Armando Genazzani, PRAC	Request for supplementary information adopted with a specific timetable.

Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Armando Genazzani, "To update the RMP for Jinarc to version 14.4 to include dehydration and pregnancy prevention programme as requiring additional risk minimisation measures in accordance with Annex II." Request for Supplementary Information adopted on 29.10.2020, 11.06.2020.	
PRAC Led **Olumiant - baricitinib - EMEA/H/C/004085/II/0017** Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final report from study I4V-MC-B010 "Rheumatologist Survey to Assess the Effectiveness of the Risk Minimisation Measures (RMM) for Olumiant" listed as a category 3 study in the RMP. This observational study was a multi-national cross-sectional survey. The RMP version 9.3 has been adopted." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 09.07.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Olumiant - baricitinib - EMEA/H/C/004085/II/0019** Eli Lilly Nederland B.V., PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on diverticulitis following a signal assessment (EPITT: 19496; Procedure EMEA/H/C/4085/SDA/010); the Package Leaflet is updated accordingly." Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Ventavis - iloprost - EMEA/H/C/000474/II/0066** Bayer AG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of an updated RMP version 8.0 to introduce respiratory tract infection as an important potential risk as requested by PRAC in the conclusions of the periodic safety update report single assessment (PSUSA) procedure (EMEA/H/C/PSUSA/00001724/201709) adopted	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

in May 2018. In addition, the MAH took the opportunity to update the RMP in line with revision 2 of GVP module V on 'Risk management systems'." Opinion adopted on 29.10.2020.	
PRAC Led **Xeljanz - tofacitinib - EMEA/H/C/004214/II/0023** Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Submission of the final report from study A3921205 listed as a category 3 study in the RMP. This is an Observational, Post-Authorization Safety Study (PASS) within the Consortium of Rheumatology Researchers of North America (CORRONA) Registry Comparing Rates of Malignancy, Cardiovascular and Serious Infection Outcomes among Patients Treated for Moderately to Severely Active Rheumatoid Arthritis. The RMP version 10.1 has also been submitted." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 11.06.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **Yondelis - trabectedin - EMEA/H/C/000773/II/0061** Pharma Mar, S.A., Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Sinan B. Sarac, "Submission of an updated RMP version 9.0 in order to reflect new available data from completed studies, removal of safety concerns, removal of a target follow-up questionnaire and update of the format in line with the guidance "EMA/164014/2018 Rev.2.0.1 accompanying GVP Module V Rev.2"." Request for Supplementary Information adopted on 29.10.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS1589** **Incruse Ellipta-EMEA/H/C/002809/ WS1589/0029** **Rolufta Ellipta-EMEA/H/C/004654/ WS1589/0014** GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Ilaria Baldelli, PRAC-	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

CHMP liaison: Armando Genazzani, "Submission of an updated RMP version 7.2 following completion of a category 3 study (WWE117397) "A Post-authorization safety Electronic Medical Records database retrospective cohort study of new users of inhaled UMEC/VI or new users of inhaled UMEC in the primary care setting". In addition, updates are included relating to the Category 1 study 201038 "Post-authorisation Safety (PAS) Observational Cohort Study to Quantify the Incidence and Comparative Safety of Selected Cardiovascular and Cerebrovascular Events in COPD Patients Using Inhaled UMEC/VI Combination, or Inhaled UMEC versus Tiotropium (Study201038)." The RMP is also updated to align with the Guidance on the Good Pharmacovigilance Practice (GVP) Module V - Risk management systems Revision 2 guidelines." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 09.07.2020.	
PRAC Led **WS1794** **Brimica Genuair-EMEA/H/C/003969/ WS1794/0029** **Duaklir Genuair-EMEA/H/C/003745/ WS1794/0029** AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra, Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final study report from study D6570R00002 listed as a category 3 study in the RMP. This is a descriptive, non-interventional, multinational European cohort study of new users of aclidinium, aclidinium/formoterol, and other selected COPD medications. The following safety concerns, listed as missing information in the RMP: 'safety in patients with hepatic or severe renal impairment', 'safety in patients with benign prostatic hyperplasia or urinary retention' and 'use in pregnancy or lactation' are removed. The updated RMP version 5.0 is acceptable." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 09.07.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS1795**	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP

Bretaris Genuair-EMEA/H/C/002706/ WS1795/0043 **Eklira Genuair-EMEA/H/C/002211/ WS1795/0043** AstraZeneca AB, Lead Rapporteur: Ewa Balkowiec Iskra, Lead PRAC Rapporteur: Adam Przybylkowski, PRAC-CHMP liaison: Ewa Balkowiec Iskra, "Submission of the final study report from study D6570R00002 listed as a category 3 study in the RMP. This is a descriptive, non-interventional, multinational European cohort study of new users of aclidinium, aclidinium/formoterol, and other selected COPD medications. The following safety concerns listed as missing information in the RMP: 'safety in patients with hepatic or severe renal impairment' and 'safety in patients with benign prostatic hyperplasia or urinary retention' are removed. The updated RMP version 8.0 is acceptable." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 09.07.2020.	Members were in agreement with the CHMP recommendation.
PRAC Led **WS1805** **Advagraf-EMEA/H/C/000712/WS1805/ 0057** **Modigraf-EMEA/H/C/000954/WS1805/ 0035** Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, Lead PRAC Rapporteur: Ronan Grimes, PRAC-CHMP liaison: Jayne Crowe, "Submission of an updated RMP version 3 in order to add a non-interventional post-authorisation safety study related to the safety concerns of use during pregnancy and use during lactation. The two important potential risks, 'Exchangeability between the granule and capsule formulations of tacrolimus' for Modigraf and 'If administered accidentally either arterially or perivascularly, the reconstituted solution may cause irritation at the injection site' for Prograf concentrate for solution for infusion, are combined into the important identified risk 'Medication errors'. The RMP is being brought to EU RMP template revision 2." Request for Supplementary Information adopted on 29.10.2020, 09.07.2020.	Request for supplementary information adopted with a specific timetable.
PRAC Led **WS1849**	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP

Thymanax-EMEA/H/C/000916/WS1849/0045 **Valdoxan-EMEA/H/C/000915/WS1849/0047** Les Laboratoires Servier, Lead Rapporteur: Bjorg Bolstad, Lead PRAC Rapporteur: Pernille Harg, PRAC-CHMP liaison: Bjorg Bolstad, "Submission of an updated RMP version 23.1 in order to revise the safety concerns, important identified and potential risks in line with the new GVP module V. In addition, the completed studies have been deleted and, as agreed in LEG 031, the frequency of the educational material distribution is updated to once a year." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 03.09.2020.	Members were in agreement with the CHMP recommendation.
PRAC Led **WS1897** **Mirapexin-EMEA/H/C/000134/WS1897/0096** **Sifrol-EMEA/H/C/000133/WS1897/0087** Boehringer Ingelheim International GmbH, Lead Rapporteur: Kirstine Moll Harboe, Lead PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll Harboe, "RMP update to implement changes requested by PRAC in the context of the PSUSA procedure (EMEA/H/C/PSUSA/00002491/201904) of the PBRER with a DLP on 06 Apr 2019: · to remove `Cardiac failure' from the list of important identified risks; · to amend the information with regard to the important identified risk `Dopamine agonist withdrawal syndrome' (DAWS)." Opinion adopted on 29.10.2020. Request for Supplementary Information adopted on 04.09.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
PRAC Led **WS1923** **Afinitor-EMEA/H/C/001038/WS1923/0068** **Votubia-EMEA/H/C/002311/WS1923/0067** Novartis Europharm Limited, Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Janet Koenig, "Submission of the Final Clinical Study Report for study CRAD001MIC03 (TOSCA), an international disease registry collecting data on	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

manifestations, interventions and outcomes in patients with tuberous sclerosis complex (TSC), for Votubia. The RMP version 15.0 is submitted to reflect the completion of MEA 14.4 (Votubia) and to remove important safety concerns as recommended by the PRAC (EMEA/H/C/WS1671)." Opinion adopted on 29.10.2020.	

B.5.5. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0026/G, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 12.11.2020, 06.11.2020. Request for Supplementary Information adopted on 09.10.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0027, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Request for Supplementary Information adopted on 06.11.2020, 09.10.2020.	Request for supplementary information adopted with a specific timetable.
Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0028/G, Orphan, ATMP Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang Opinion adopted on 12.11.2020, 06.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0006, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Johannes Hendrikus Ovelgonne, CHMP Coordinator: Johann Lodewijk Hillege Opinion adopted on 12.11.2020, 06.11.2020. Request for Supplementary Information adopted on 09.10.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Zolgensma - onasemnogene abeparvovec - EMEA/H/C/004750/II/0007/G, Orphan, ATMP Novartis Gene Therapies EU Limited, Rapporteur: Johannes Hendrikus Ovelgonne, CHMP Coordinator: Johann Lodewijk Hillege Request for Supplementary Information adopted	Request for supplementary information adopted with a specific timetable.

on 06.11.2020.	

B.5.6. CHMP-PRAC-CAT assessed procedures

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS1811 **Olanzapine Glenmark-EMEA/H/C/001085/ WS1811/0034** **Olanzapine Glenmark Europe-EMEA/H/C/001086/WS1811/0031** **Olazax-EMEA/H/C/001087/WS1811/0027** **Olazax Disperzi-EMEA/H/C/001088/ WS1811/0029** Glenmark Arzneimittel GmbH, Generic, Generic of Olansek (SRD), Zyprexa, Zyprexa Velotab, Lead Rapporteur: Alexandre Moreau Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 17.09.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1829 **Aldurazyme-EMEA/H/C/000477/WS1829/ 0076** **Evoltra-EMEA/H/C/000613/WS1829/0070** **Fasturtec-EMEA/H/C/000331/WS1829/ 0059** **Rilutek-EMEA/H/C/000109/WS1829/0064** **Zaltrap-EMEA/H/C/002532/WS1829/0057** sanofi-aventis groupe, Lead Rapporteur: Filip Josephson, "To update the product information with respect to the excipient Sodium in accordance with the updated annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668). The Product Information was also brought in line with the latest QRD template. Finally, the MAH took the opportunity to implement an update of the phone number for the local representative for Italy, Malta Netherlands and Slovakia in section 6 of the Package Leaflet for all products." Opinion adopted on 12.11.2020. Request for Supplementary Information adopted on 17.09.2020, 23.07.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1854	Positive Opinion adopted by consensus on

Renvela-EMEA/H/C/000993/WS1854/0053 **Sevelamer carbonate Winthrop-EMEA/H/C/003971/WS1854/0026** Genzyme Europe BV, Lead Rapporteur: Karin Janssen van Doorn, "To update section 2 of the SmPC, labelling and section 2 of the PL for the Powder for oral suspension presentations for Renvela and Sevelamer carbonate Winthrop to clarify the exact quantity and threshold of Propylene glycol per product following the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668). The MAH took the opportunity to include an update about the local representatives in the Pl for Italy, Malta, The Netherlands and Slovakia." Opinion adopted on 12.11.2020.	12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1864/G **Kivexa-EMEA/H/C/000581/WS1864/0086/G** **Trizivir-EMEA/H/C/000338/WS1864/0118/G** **Ziagen-EMEA/H/C/000252/WS1864/0113/G** ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race Opinion adopted on 22.10.2020. Request for Supplementary Information adopted on 03.09.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1902/G **Ambirix-EMEA/H/C/000426/WS1902/0109/G** **Fendrix-EMEA/H/C/000550/WS1902/0072/G** **Infanrix hexa-EMEA/H/C/000296/WS1902/0281/G** **Twinrix Adult-EMEA/H/C/000112/WS1902/0144/G** **Twinrix Paediatric-EMEA/H/C/000129/WS1902/0145/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 22.10.2020.	Positive Opinion adopted by consensus on 22.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1913/G **Infanrix hexa-EMEA/H/C/000296/WS1913/0282/G** GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke	Positive Opinion adopted by consensus on 06.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 06.11.2020.	
WS1932 **Ultibro Breezhaler-EMEA/H/C/002679/ WS1932/0034** **Ulunar Breezhaler-EMEA/H/C/003875/ WS1932/0035** **Xoterna Breezhaler-EMEA/H/C/003755/ WS1932/0038** Novartis Europharm Limited, Lead Rapporteur: Kirstine Moll Harboe, "To update sections 4.4 and 5.1 of the SmPC related to QT interval prolongation by deleting this reference from the "Warnings and Precautions" section of the proposed SmPC. In addition the MAH has brought the annexes in line with the latest QRD template and a mainly format driven update of the SmPC section 6.6 and PL (i.e. addition of bullets, underline, bold/unbold text, adding spaces between lines etc.)." Opinion adopted on 12.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1933/G **Blitzima-EMEA/H/C/004723/WS1933/ 0036/G** **Ritemvia-EMEA/H/C/004725/WS1933/ 0036/G** **Truxima-EMEA/H/C/004112/WS1933/ 0039/G** Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz Opinion adopted on 29.10.2020.	Positive Opinion adopted by consensus on 29.10.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1934 **Azacitidine Celgene-EMEA/H/C/005300/ WS1934/0002** **Vidaza-EMEA/H/C/000978/WS1934/0050** Celgene Europe BV, Lead Rapporteur: Paula Boudewina van Hennik, "To update the SmPC sections 4.2, 4.8, 5.1 and 5.2 to reflect the outcome of EMEA/H/C/000978/P46/034 where the paediatric information was updated."	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
WS1947/G **Blitzima-EMEA/H/C/004723/WS1947/ 0037/G** **Ritemvia-EMEA/H/C/004725/WS1947/ 0037/G** **Truxima-EMEA/H/C/004112/WS1947/ 0040/G** Celltrion Healthcare Hungary Kft., Duplicate, Duplicate of Truxima, Lead Rapporteur: Sol Ruiz	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 12.11.2020.	
WS1948 **Viagra-EMEA/H/C/000202/WS1948/0107** Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, "To update section 4.4 of the SmPC and section 2 of the PL of the Product information for Viagra, Verventi and Sildenafil Pfizer SmPCs in line with the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The MAH has proposed wording in the SmPC to correspond to the excipient guideline PIL wording relevant to patients with low sodium diets. The MAH has also taken the opportunity to correct an inaccuracy in the current Viagra 25 mg, 50 mg and 100 mg film-coated tablet SmPC related to the quantity of lactose calculated to be present in each tablet. For Sildenafil Pfizer and Verventi, the SmPCs have been amended to specify the quantity of lactose rather than the quantity of lactose monohydrate thus aligning the text with that of the Viagra SmPC." Opinion adopted on 12.11.2020.	Positive Opinion adopted by consensus on 12.11.2020. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.9. Information on withdrawn type II variation / WS procedure

B.5.10. Information on type II variation / WS procedure with revised timetable

WS1820 **Iscover-EMEA/H/C/000175/WS1820/0142** **Plavix-EMEA/H/C/000174/WS1820/0140** sanofi-aventis groupe, Lead Rapporteur: Bruno Sepodes, Lead PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of section 4.2 of the SmPC in order to add 600 mg as an alternative loading dose to the existing 300 mg to be used at initiation of treatment in the indication "Secondary prevention of atherothrombotic events in adult patients suffering from acute coronary syndrome ". This update is based on a bibliographic review of published studies. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."	Request by the applicant for an extension of the clock-stop to respond to the RSI adopted on 15.10.2020. The CHMP agreed to the request by the applicant.

Request for Supplementary Information adopted on 15.10.2020, 25.06.2020.	
Xenical - orlistat - EMEA/H/C/000154/II/0083 CHEPLAPHARM Arzneimittel GmbH, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 15.10.2020.	Request by the applicant for an extension of the clock-stop to respond to the RSI adopted on 15.10.2020. The CHMP agreed to the request by the applicant.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

arachis hypogaea extract - EMEA/H/C/004810, Article 28
treatment of peanut allergy

aducanumab - EMEA/H/C/005558
Alzheimer's disease

lenadogene nolparvovec - EMEA/H/C/005047, Orphan, ATMP
GenSight Biologics S.A., treatment of vision loss due to Leber Hereditary Optic Neuropathy (LHON)

anifrolumab - EMEA/H/C/004975
indicated as an add-on therapy for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), despite standard therapy

avacopan - EMEA/H/C/005523, Orphan
Vifor Fresenius Medical Care Renal Pharma France, Treatment of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

tecovirimat - EMEA/H/C/005248
treatment of orthopoxvirus disease

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Cosentyx - secukinumab - EMEA/H/C/003729/X/0067
Novartis Europharm Limited, Rapporteur: Tuomo Lapveteläinen, PRAC Rapporteur: Eva A. Segovia, "Extension application to introduce a new strength of 75 mg solution for injection."

Rinvoq - upadacitinib -

EMEA/H/C/004760/X/0006/G

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension application to introduce a new strength (30 mg prolonged-release tablet), grouped with a type II variation (C.I.6.a) to add a new indication (treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy for Rinvoq). As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC as well as the Package Leaflet are updated. The RMP (version 4.0) is updated in accordance. In addition, the marketing authorisation holder (MAH) took the opportunity to include a minor update in the Annex II."

Vosevi - sofosbuvir / velpatasvir / voxilaprevir - EMEA/H/C/004350/ X/0045/G

Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins, "Extension application to introduce a new strength (200 mg /50 mg /50 mg film-coated tablets). The new presentation is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older OR weighing at least 30 kg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 12 years and older OR weighing at least 30 kg to the existing presentation. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.2) is updated in accordance."

Xeljanz - tofacitinib - EMEA/H/C/004214/X/0030/G

Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, "Extension application to add a new strength (22 mg prolonged-release tablet) grouped with a type II variation C.I.4: Update of sections 4.1, 4.2, 4.4 , 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to

either conventional therapy or a biologic agent; as an alternative to the immediate release film-coated tablets; section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of UC. The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted."

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

idecabtagene vicleucel -
EMEA/H/C/004662, Orphan, ATMP
Celgene Europe BV, treatment of multiple myeloma
List of Questions adopted on 11.09.2020.

B.6.4. Annual Re-assessments: timetables for adoption

Myalepta - metreleptin -
EMEA/H/C/004218/S/0014, Orphan
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam Przybylkowski

Raxone - idebenone -
EMEA/H/C/003834/S/0023, Orphan
Santhera Pharmaceuticals (Deutschland) GmbH, Rapporteur: John Joseph Borg, PRAC Rapporteur: Amelia Cupelli

Vedrop - tocofersolan -
EMEA/H/C/000920/S/0039
Recordati Rare Diseases, Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Melinda Palfi

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

CABOMETYX - cabozantinib -
EMEA/H/C/004163/R/0018
Ipsen Pharma, Rapporteur: Bjorg Bolstad, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst

Epclusa - sofosbuvir / velpatasvir -
EMEA/H/C/004210/R/0054
Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Ana Sofia Diniz Martins

Qtern - saxagliptin / dapagliflozin -

EMEA/H/C/004057/R/0030
AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Ilaria Baldelli

Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/R/0026
Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ana Sofia Diniz Martins

Zoely - nomegestrol acetate / estradiol - EMEA/H/C/001213/R/0055
Theramex Ireland Limited, Rapporteur: Jean-Michel Race, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Adrien Inoubli

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

BLINCYTO - blinatumomab - EMEA/H/C/003731/II/0038, Orphan
Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová, "Extension of indication to include the use of blinatumomab as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as consolidation therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted."

Jardiance - empagliflozin - EMEA/H/C/002677/II/0055
Boehringer Ingelheim International GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Eva A. Segovia, "Extension of indication to include treatment of adult patients with heart failure and reduced ejection fraction for Jardiance; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9 and 5.1 of the SmPC are updated. This is based on final results from the EMPEROR HFrEF study, a phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo. The Package Leaflet and Labelling are

updated in accordance. Version 15.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Jyseleca - filgotinib - EMEA/H/C/005113/II/0001
Gilead Sciences Ireland UC, Rapporteur: Kristina Dunder, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nikica Mirošević Skvrce, "C.I.6 (Extension of indication) C.I.6a (Extension of indication). Extension of indication to include the treatment of active ulcerative colitis in adults patients for Jyseleca. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated accordingly. Version 1.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to do minor updates to the Annex II and to implement minor editorial changes in the SmPC and Package Leaflet."

Nucala - mepolizumab - EMEA/H/C/003860/II/0035
GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the local (IT) representative in the PL."

Nucala - mepolizumab - EMEA/H/C/003860/II/0036/G
GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala (mepolizumab); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2

of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the local representative (IT) in the PL. 2 Variations : type I B.11.e.5.a.2 To add a new pack size . As a consequence, sections 6.5 and 8 of SmPCs and section 6 of the PLs are updated accordingly. Annex IIIA is also being updated to include information relating to the new pack sizes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)	
Nucala - mepolizumab - EMEA/H/C/003860/II/0037 GlaxoSmithKline Trading Services Limited, Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Extension of indication to include hypereosinophilic syndrome (HES) for Nucala (mepolizumab); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 (in addition 6.6 for the powder for solution for injection ONLY) of the SmPC. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the Marketing authorisation holder took the opportunity to update the local representative (IT) in the PL."	
Teysuno - tegafur / gimeracil / oteracil - EMEA/H/C/001242/II/0045 Nordic Group B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include treatment of metastatic colorectal cancer in adult patients where it is not possible to initiate or continue treatment with another fluoropyrimidine. As a consequence, sections 4.1, 4.2, 4.3, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10 of the RMP has also been submitted."	
WS1937/G **Eucreas-EMEA/H/C/000807/WS1937/0080/G** **Icandra-EMEA/H/C/001050/WS1937/**	

0083/G **Zomarist-EMEA/H/C/001049/WS1937/0082/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study). Existing warning on drugs that may affect renal function or metformin disposition was expanded to include drugs that inhibit renal transporter (OCT2/MATE inhibitors) and corresponding update in Drug Interaction (sections 4.4 and 4.5). PI update to QRD v10.1."	
WS1938/G **Galvus-EMEA/H/C/000771/WS1938/0066/G** **Jalra-EMEA/H/C/001048/WS1938/0068/G** **Xiliarx-EMEA/H/C/001051/WS1938/0066/G** Novartis Europharm Limited, Lead Rapporteur: Kristina Dunder, "Modification of approved therapeutic indication to simplify wording. Update of SmPC section 5.1 to add VERIFY study data (new study)."	

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Idacio - adalimumab - EMEA/H/C/004475/II/0007 Fresenius Kabi Deutschland GmbH, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 12.11.2020.	Request for supplementary information adopted with a specific timetable.
Strensiq - asfotase alfa - EMEA/H/C/003794/II/0050, Orphan Alexion Europe SAS, Rapporteur: Armando Genazzani	
WS1982 **Aflunov-EMEA/H/C/002094/WS1982/0065** **Foclivia-EMEA/H/C/001208/WS1982/0061** Seqirus S.r.l, Lead Rapporteur: Armando Genazzani	

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

B.6.10. CHMP-PRAC assessed procedures

B.6.11. PRAC assessed procedures

PRAC Led
WS1972
Exviera-EMEA/H/C/003837/WS1972/0049
Viekirax-EMEA/H/C/003839/WS1972/0060
AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Maria del Pilar Rayon, "To provide an updated Risk Management Plans (RMP) for Viekirax and Exviera following the outcome of procedure EMEA/H/C/PSA/J/0055 to change the due date for submission of the final study report for the HCC recurrence PASS study ."

B.6.12. CHMP-CAT assessed procedures

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS1940
Adcirca-EMEA/H/C/001021/WS1940/0033
Cialis-EMEA/H/C/000436/WS1940/0093
Tadalafil Lilly-EMEA/H/C/004666/WS1940/0006
Eli Lilly Nederland B.V., Lead Rapporteur: Maria Concepcion Prieto Yerro, "To include the excipient guidance in the labelling and package leaflet annex. In addition the QRD template has also been implemented. i.e. the MAH has updated the order of presentation in line with QRD for Cialis and Tadalafil Lilly.
The details of the local representatives in Lithuania, Latvia, Estonia, France and Slovakia have been updated ."

WS1950
Kinzalmono-EMEA/H/C/000211/WS1950/0116
Micardis-EMEA/H/C/000209/WS1950/0119

Pritor-EMEA/H/C/000210/WS1950/0129
Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, "To update section 4.4 of the SmPC and section 2 of the PL in order to implement the wording in compliance with the revised "Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668), Revision 1 related to sorbitol and sodium content.
Furthermore, MAH took this opportunity to implement QRD template version 10.1.
Section 6 of the PL was updated to add 'K25' to povidone.
Finally, some editorial changes to correct the provided administrative information of the PI are included in the submission:
- For Kinzalmono/Pritor:
§ Correction of the date of latest renewal in section 9 of the SmPC.
§ Change of the phone number of local representative of MAH in Bulgaria in section 6 of PL.
- For Micardis:
§ Change of the phone number of local representative of MAH in Austria and Lithuania in section 6 of PL.
§ Removal of "D-" from the zip code of address of MAH and manufacturer in section 7 of the SmPC, section A of the Annex II, section 6 of the PL and section 11 of the Labelling.
- Addition of minor linguistic corrections to the PI of the following languages: LT, FI, SV and EL.
Further the MAH took the opportunity and include an editorial change , as agreed with EMA during procedure EMEA/H/C/xxxx /IG1261."

WS1951
Combivir-EMEA/H/C/000190/WS1951/0098
Telzir-EMEA/H/C/000534/WS1951/0102
ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "To update section 4.4 of the SmPC and section 2 of the PL to update excipients labelling in alignment with excipients guideline (Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668) related to sodium content for:

- Telzir (fosamprenavir) 700 mg Film-coated tablets;
- Combivir (lamivudine/zidovudine) 150/300 mg Film-coated tablets.
In addition, the MAH took the opportunity to apply minor administrative changes in the following languages: LT, SL and FR."

WS1955
Exelon-EMEA/H/C/000169/WS1955/0130
Prometax-EMEA/H/C/000255/WS1955/0130
Novartis Europharm Limited, Lead Rapporteur: Alexandre Moreau, "To update sections 2 and 4.4 of the SmPC for Exelon 2 mg/mL Oral Solution and Prometax 2 mg/mL Oral Solution in line with the current excipients guideline (Annex to the European Commission guideline on `Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668)) with regards to sodium (from sodium benzoate and sodium citrate dihydrate) and sodium benzoate that are listed under the annex to the excipient guideline. Section 2 of package leaflet (PL) was updated accordingly. In addition, the MAH took this opportunity to bring the product information annexes for all presentations in line with the current QRD template."

WS1956
Zypadhera-EMEA/H/C/000890/WS1956/0043
Zyprexa-EMEA/H/C/000115/WS1956/0130
Zyprexa Velotab-EMEA/H/C/000287/WS1956/0098
Eli Lilly Nederland B.V., Duplicate, Duplicate of Zyprexa, Lead Rapporteur: Outi Mäki-Ikola, "To include new wording on excipients in SmPC section 4.4 and in the package leaflet. The wording takes the new excipient guidance into account. In addition, the MAH has also taken this opportunity to make minor changes in accordance with the QRD template."

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Timetables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures	Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

F.1. Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. Ongoing procedures

G.3. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.3.1. List of procedures concluding at 09-12 November 2020 CHMP plenary:

Oncology	
Lacutamab, Treatment of patients with Sézary Syndrome who have received at least two prior systemic therapies	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Dermatology	
Treatment of moderate to severe chronic hand eczema in adults with a history of inadequate response to TCS or when TCS is medically inadvisable	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Treatment of atopic dermatitis	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Neurology	
Treatment of Parkinson's disease	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Pneumology-allergology	
Brensocatib, Treatment of non-cystic fibrosis bronchiectasis	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Vaccines	
VAC18193, Active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults	The CHMP granted eligibility to PRIME and adopted the critical summary report.

G.3.2. List of procedures starting in November 2020 for December 2020 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address